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O
n November 29, 2018, experts in the ﬁeld of
infectious diseases, pathogen reduction technol-
ogies (PRTs) and other participants from blood
centers, academia, and industry gathered at the
Food and Drug Administration (FDA) White Oak Campus in
Silver Spring, Maryland, for a 2-day public workshop entitled
“Pathogen Reduction Technologies for Blood Safety.” The
workshop opened with welcome remarks from Dr. Nicole
Verdun, Director, Ofﬁce of Blood Research and Review
(OBRR), Center for Biologics Evaluation and Research
(CBER), FDA, followed by introductory remarks from
Dr. Peter Marks, Director, CBER, FDA. The ﬁrst day of the
workshop focused on blood-borne infectious agents and
their impact on blood safety, experiences of the American
Red Cross, and other blood establishments in implementing
FDA-approved pathogen inactivation (PI) technology for
plasma and platelets (PLTs) in the United States and novel
PRTs under consideration for whole blood (WB) and red
blood cells (RBCs).
The second day opened with welcome remarks from
Dr. Chintamani Atreya, Associate Director for Research,
OBRR, CBER, FDA. The focus was on emerging innovations
relevant to PRTs and potential alternatives to PRTs. The
workshop concluded with remarks on insights for future
research and development in this area for blood and blood
product safety from infectious agents.
A brief introduction of each session by the session mod-
erator followed by a summary of the speaker presentation as
submitted by the moderator and speaker are reported here.
SESSION 1: BLOOD-BORNE INFECTIOUS
AGENTS AND THEIR IMPACT ON BLOOD
SAFETY
Introduction. Moderator—Simone Glynn, MD, MPH
The ﬁrst session titled “Blood-Borne Infectious Agents and
Their Impact on Blood Safety” provides a state-of-the-science
overview of the risks to blood safety posed by infectious agents.
Additionally, this session addresses the strategies used to
mitigate these risks in the United States including the introduc-
tion of increasingly sensitive laboratory screening testing
platforms and PRTs for PLTs and plasma products. In a ﬁrst
part, the session includes a general overview of the evolution
of responses to established, emerging, and reemerging
transfusion-transmitted infectious diseases in the past 50 years.
Further, it addresses the need for ongoing surveillance for and
systematic responses to emerging infectious diseases (EIDs),
optimally with sensitive metagenomics, multiplexed nucleic
acid ampliﬁcation technology (NAT) and serologic testing
strategies in sentinel global donor populations. This is followed
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by a review of the major policy issues pertaining to the devel-
opment and implementation of PRTs, which if successfully
adopted will provide insurance against known and unknown
pathogens that may enter the blood supply. It will be noted
that these technologies, if applied to all blood components or
WB, may allow for the relaxation of redundant donor labora-
tory screening, modiﬁed donor questioning and/or deferral,
and simpliﬁed handling of postdonation information while
preserving or enhancing the safety of the blood supply. The
session ends with an overview of the current status of
approved pathogen-reduced (PR) PLT and plasma products in
the United States with attention provided to their current effec-
tiveness and safety proﬁle. Major reasons for the slow adoption
of the currently approved PR products in the United States are
discussed including cost-effectiveness (CE) considerations.
Risk to the blood safety from infectious agents—
Michael Busch, MD
Speaker’s summary: Blood donor screening began in the 1940s
with testing for syphilis, followed in the early 1970s by testing
for hepatitis B surface antigen. The discovery of human immu-
nodeﬁciency virus (HIV), human T-lymphotropic viruses, and
hepatitis C virus (HCV) and introduction of progressively more
sensitive serological assays targeting virus-speciﬁc antibodies
and antigens for these “classic” transfusion-transmitted infec-
tions (TTIs) in the 1980s and 1990s was effective in interdicting
the majority of infectious blood donations.1 Implementation of
NAT screening for HIV, HCV, and hepatitis B virus (HBV) fur-
ther reduced the residual risk of infectious window period
donations, such that per-unit risks are less than one in
1,000,000 in the United States (Fig. 1).2–4
We now recognize that in addition to classic TTIs that
establish chronic infection, agents that cause acute transient
infections may also be TTI at signiﬁcant rates if there are large
epidemics or recurrent seasonal transmission.5–7 Salient
examples of EIDs where interventions were implemented
in the United States include nationwide screening of donors
for Trypanosoma cruzi using a one-time antibody testing
strategy,8 NAT testing for West Nile virus (WNV)9,10 and Zika
virus (ZIKV),11,12 and testing for Babesia microti in endemic
regions.13,14 Testing for bacterial contamination of PLT com-
ponents was instituted in the 2000s to prevent septic transfu-
sion reactions.15 Donor deferrals were also implemented to
reduce other risks including variant Creutzfeldt-Jakob disease
and several other agents.16 Fig. 1 lists the EIDs for which inter-
ventions were implemented over the past two decades.
The emergence of EIDs has proven to be unpredictable,
as is their risk to blood safety.5–7 EIDs of concern span all
pathogen classes, with 60% being from zoonotic sources. The
AABB has developed “Fact Sheets” (available at http://www.
aabb.org/tm/eid/Pages/default.aspx) that provide information
on agent classiﬁcation, background on pathogenesis and
clinical syndromes, modes of transmission [including
vectors/reservoirs], likelihood of transfusion transmission
[TT] and information on known transmission cases, feasibility
and predicted success of interventions that could be used for
donor qualiﬁcation [questioning], tests available for donor
screening, and efﬁcacy of PRTs).
Proactive surveillance and research to evaluate responses
to potential EID threats to blood safety have been adopted
through collaborative initiatives of NIH, FDA, CDC, AABB,
and blood research organizations.5–7 An unintended conse-
quence has been the identiﬁcation of agents found through
viral discovery programs using metagenomics technologies
that can theoretically be transmitted by transfusion but which,
upon subsequent investigation, prove not to be (Fig. 1). The
most striking example of this was xenotrophic murine
leukemia–related virus, which was reported to be associated
with prostate cancer and later chronic fatigue syndrome and
to be present in the blood of asymptomatic blood donors.17
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subsequently determined that xenotrophic murine leukemia–
related virus did not affect humans and was a laboratory
contaminant from cell lines that contained this murine
virus.18 These experiences led to the US National Heart, Lung
and Blood Institute (NHLBI) and FDA to convene workshops
focused on proactive but rational and systematic responses to
EIDs.6,7 The Alliance of Blood Operators developed a “risk-
based decision-making” process that includes formalized
methods for quantifying risk and evaluating interventions.19
The 2015 to 2017 ZIKV pandemic is illustrative of the
ongoing challenge of balancing timely and precautionary
responses to emerging TTI threats with logistic and eco-
nomic considerations. As the epidemic expanded in the
Americas and the association of ZIKV with severe fetal out-
comes emerged along with several cases of probable TT, the
FDA mandated implementation of individual-donation (ID)-
NAT or PRT of PLTs throughout the United States in
2016.11,12 After 2 years of ID-NAT with very low yield at an
annual cost of $137 million, the FDA ZIKV policy was
revised to allow for minipool NAT with ID-NAT triggered
during future epidemics, similar to successful screening for
WNV. Nonetheless, ZIKV testing now represents a theoreti-
cal beneﬁt at a high cost, precipitating consideration of
regional screening policies and an urgent need to further
deﬁne “tolerable risk” in the blood safety arena.20
Pathogen reduction: an overview of policy issues—
Steve Kleinman, MD
Speaker’s summary: Pathogen inactivation and/or reduction
should be viewed in the context of shifting the blood safety
paradigm from reactive to proactive thereby providing
insurance against known and unknown pathogens that may
enter the blood supply or are currently un(der)recognized.
Based on the positive experience of PI for plasma deriva-
tives (e.g., no HIV, HCV, or HBV transmission since 1987), it
seems reasonable to apply this safety paradigm to blood
components. Of note, a consensus conference held in
Canada in 2007 issued recommendations in favor of rapid
adoption of a PI technology even if it could not be applied
to the full range of blood components. Despite these recom-
mendations, PI technology for PLTs has been slow to be
adopted in the United States. As described in Table 1, the
reasons for this are many but it appears that the predomi-
nant impediment has been cost.
When evaluating current blood safety risks and the
need for additional interventions, it is important to under-
stand that most often these risks are expressed on a per-unit
basis and represent the likelihood of the agent surviving
during storage in a particular type of blood component
(e.g., plasma, PLTs, or RBCs). The risk of TT of an agent
and/or the occurrence of symptomatic or serious disease is
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Fig. 1. Per-unit infectious risk for HBV, HCV, and HIV from 1980 to 2018 and emerging infectious agents that were investigated for
potential TT over the past 25 years. Agents proven to be blood safety threats for which interventions were implemented are in red,
agents that were established to be legitimate infectious agents but not TT or associated with diseases are in blue, and alleged threats that
were determined to not cause human infections or due to artifacts are shown in green. No interventions for HEV have yet been
implemented in the United States, but interventions have been implemented in some countries where HEV incidence is higher.
ICL = idiopathic CD4+ T-lymphocytopenia; HGV = hepatitis G virus; SFV = simian foamy virus; PTLV = primate T-cell lymphotrophic
viruses; SARS = severe acute respiratory syndrome; PARV-4 = parvovirus type 4; SFTSV = severe fever with thrombocytopenia virus;
MERS-CoV = Middle Eastern respiratory syndrome coronavirus; Ab = antibody; Ag = antigen; HBsAg = hepatitis B surface antigen;
vCJD = variant Creutzfeldt-Jakob disease. This ﬁgure was updated from Perkins and Busch.1 [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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likely to be less than this per-unit exposure risk. On the
other hand, these risk estimates are for single-unit transfu-
sions; risk will be higher (i.e., multiplied by the number of
units) for the majority of patients who receive multiple
units, either in single exposures or over a treatment course.
Assuming that therapeutic product efﬁcacy is maintained
and cost issues can be addressed, the goal is to have all blood
components (RBCs, PLTs, plasma) or WB (before component
separation) treated by PI—this could then allow for the relaxa-
tion of redundant donor laboratory screening, modiﬁcation of
donor questioning and/or deferral, simpliﬁed handling of
postdonation information, and elimination of the need for
irradiation of cellular components to prevent transfusion-
associated graft-versus-host disease (TA-GVHD). Potential
blood screening changes include eliminating syphilis, T. cruzi,
cytomegalovirus (CMV), and Babesia testing; modifying the
menu of HBV tests; eliminating off-season WNV and ZIKV
testing; and eliminating ID-NAT. A fully PI-treated blood sup-
ply would shape the response to threats from new enzyme
immunoassays in that there would be less pressure to develop
laboratory screening assays.
Additional important considerations in evaluating the
role of PI in blood safety policy are that not all infectious
agents are inactivated by PI technology (nonenveloped
viruses and prions show variable resistance) and each man-
ufacturer’s process must be independently evaluated for
quantitative levels of inactivation of numerous known path-
ogens as well as for therapeutic efﬁcacy of the treated com-
ponent and potential adverse effects in the recipient. The
health care reimbursement system must also be able to
accommodate the cost.
Current status of pathogen-reduced platelets in the
United States—Edward Snyder, MD, FACP, and
Sara Rutter, MD
Speaker’s summary: Pathogen-reduced PLTs manufactured
using a synthetic psoralen compound (amotosalen) are
approved by the FDA for use by all patient demographics.21–24
Currently this is the only PLT PR manufacturing system
approved by the FDA in the United States. It requires ultravio-
let (UV)-A light activation of the psoralen photochemical to
enable it to function as the inactivation agent.21–25 Approval is
limited to single-donor PLTs collected using either of two
apheresis devices and stored in a PLT additive solution, PAS-
C, or in autologous donor plasma, depending on the aphere-
sis device used for manufacture. Both PR products have a
5-day shelf life at 20 to 24C.23
The psoralen product currently is being evaluated in
PIPER, a Phase IV postmarketing study. Other manufactur-
ing systems are under varying degrees of development.26,27
One of these systems uses a different light-activated photo-
chemical, riboﬂavin, and is currently being evaluated in the
United States in a Phase III randomized clinical trial,
MIPLATE.28 A third PR technology uses a shorter wave-
length of UV light (UVC), as the sole mechanism of inactiva-
tion.27,29,30 It, too, is being evaluated in CAPTURE, a Phase
III clinical trial in Europe.
Major beneﬁts of PR PLTs include:
• Multilog inactivation of most blood-borne pathogens;23,24
• Inactivation of lymphocytes thus protecting against TA-
GVHD.23,24
Despite FDA approval and the acknowledged beneﬁts
of the technology, however, the medical ﬁeld has been slow
to adopt and integrate PR technology into day-to-day hospi-
tal operations.
Reasons for this slow adoption include concerns over
the possibility of:
• Lower posttransfusion corrected count increment in PR
PLTs versus conventional PLTs;
• Lower hemostatic efﬁcacy of PR PLTs versus conven-
tional PLTs;
• Higher risk of TA-GVHD since gamma or x-radiation of
the PR PLTs is not recommended;
• Toxicity from repeated administration of psoralen—in
adults and especially in neonates and children;27,30
• An increase in the incidence of transfusion reactions
due to PR PLTs;
• Occurrence of skin rashes in neonates exposed to blue
light therapy for hyperbilirubinemia;30
• Increased cost associated with use of PR PLTs versus
conventional PLTs.27
Many of these concerns have been addressed in publi-
shed studies. Importantly, clinical reports have shown PR
PLTs to be clinically acceptable.31–36 FDA has provided draft
guidance, but to date the Agency has stopped short of
encouraging use of PR technology.21 Thus, it is left up to
individual hospitals as to whether they adopt, or refrain
from, use of PR PLT technology.
Currently the biggest ongoing credible blood-borne
pathogen threat to the nation’s blood supply comes from
bacterial contamination.37 While PR technology can address
this, there are other options for mitigating risk of bacterial
contamination of PLTs, including performing secondary
bacterial cultures and point-of-release immunologic testing.
However, should a new viral or other nonbacterial agent
TABLE 1. Reasons for slow adoption of PR PLTs in
the United States
Current safety of the volunteer blood supply
Success of surveillance and screening in dealing with emerging
pathogens
Inability of current technologies to inactivate all agents (small
nonencapsulated viruses, spores, high titers of virus, and
prions)
Efﬁcacy concerns
No single method to treat all components
Regulatory requirements
Cost
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threaten the national blood supply, the time to ramp up
adequate PR manufacturing infrastructure to meet such a
nonbacterial threat would likely be substantial.38 More
widespread adoption of PR technology now would do much
to ameliorate the concern over this scenario.
Overall, the use of PR technology is slowly increasing,
and data addressing many of the above-listed concerns are
being reported, at least in abstract form.31–36 However, the
lack of an extensive degree of published US data, especially
for pediatric and transplant recipients, coupled with the
absence of a strong FDA endorsement of the technology and
the high cost of this technology, has hampered widespread
acceptance of PR PLTs.30 The possibility of another blood-
borne threat to the safety of the national blood supply seems
inevitable. How well we mitigate that threat may well depend
on how these issues regarding PR blood products are
resolved. It is critical that early adopters of PR technology in
the United States publish their experience with utilization of
PR PLTs for patient care, especially their pediatric experience.
Pathogen reduction technology for plasma in the
United States—James P. AuBuchon, MD, FACP,
FRCP (Edin)
Speaker’s summary: Two methods of PR plasma are currently
licensed and available in the United States, solvent/detergent
(S/D)-treated plasma (SD plasma; Octaplas, Octapharma) and
amotosalen/UV-treated plasma (Intercept plasma, Cerus Cor-
poration). Plasma treated with riboﬂavin and UV (Mirasol
plasma; Terumo BCT) is part of a similar system being devel-
oped for other components and is also included in this
summary.
Each of the techniques results in a reduction of the con-
tent and/or activity of the pro- and anticoagulant proteins in
plasma. In general, these reductions do not exceed 20% to
30%, and for many proteins the reduction is less than this.
The most notable reductions are in ﬁbrinogen and Factors (F)
VIII and FV across all platforms; F IX and FXI, protein C, and
large von Willebrand factor multimers with Mirasol; and
protein S and antiplasmin with Octaplas.39–45 There have been
few investigations of these treatments on complement com-
ponents; in an analysis of Intercept plasma, C3a was found to
be reduced.45 It has been noted that the reductions, while sig-
niﬁcant, usually resulted in contents within the reference
range.39 The pooled nature of SD plasma greatly reduces the
variability in content that can easily be demonstrated between
different donors’ plasma samples.46 Cryoprecipitate may be
prepared from Intercept and Mirasol plasma units to meet the
minimum content requirements, although the effect of the
treatment is still evident.47,48
In vitro analyses of the clotting system have generally
demonstrated substantial retention of clinically relevant func-
tion.42,44 As might be expected from the reduced contents
noted, the resulting ﬁbrin strands are thinner (with resulting
increased clot density and reduced permeability) with longer
lag time for formation or prolonged time to lysis.49
Multiple clinical trials have demonstrated expected out-
comes with the use of these PR plasma samples. Prophylactic
transfusion of Intercept plasma into congenitally deﬁcient
patients yielded expected increases in the deﬁcient factor in
circulation with anticipated half-lives.39 Use of large volumes
of Intercept plasma in plasma exchanges for thrombotic
thrombocytopenic purpura or idiopathic thrombocytopenic
purpura resulted in expected outcomes without generating
adverse events or (new) coagulopathy.50–52 Use of large vol-
umes (approx. 2 L) of Intercept plasma in liver transplantation
yielded the same outcomes as with quarantine plasma.50–53
The current formulation of Octaplas has not been reported to
be associated with thrombotic events when used in large vol-
umes as had been seen with the original version of SD
plasma.54
A theoretical question has been raised whether the
reduced content these components might place massive
transfusion recipients at increased risk of inadequate hemo-
stasis and death.55 One in vitro mixing study suggested that a
50% plasma replacement would be necessary before altering
coagulation kinetics.56 Several large, historically controlled
experiences with Intercept plasma in trauma situations, how-
ever, have failed to show any impact on the need for other
blood components, time to discharge or mortality.32
These PR plasma samples have not been associated with
increased adverse events after transfusion.57 Because of the
pooled basis of SD plasma, it is believed to carry a reduced
risk of transfusion-related acute lung injury (TRALI) because
of dilution of potentially offending antibodies. There have
been no TRALI cases reported in more than 10 million
Octaplas units transfused.58,59 If the existing risk of TRALI is
greater than one in 5000, removal of this risk in itself makes
use of SD plasma cost-effective.60 This pooling, however, does
increase the risk of early and wide dissemination of a nascent
nonenveloped virus.61
To date, there has been little uptake of PR plasma in
the United States outside of Octaplas for patients with
severe allergic reactions to single-donor plasma. This is
probably due to the perception of viral safety (and lack of
bacterial contamination risk) in standard plasma and the
increased cost of these newer plasmas. Widespread intro-
duction likely will follow only after implementation of simi-
lar systems for PLTs and RBCs despite admonishments from
a consensus conference and demonstration of the impor-
tance of plasma transmission of new pathogens.
SESSION 2: IMPLEMENTATION OF PRT FOR
BLOOD PRODUCTS IN THE UNITED STATES
Introduction. Moderator—Willy Albert Flegel, MD
Four years have passed since approval of a PRT devices for
PLTs and plasma products by the FDA. The ﬁve presenta-
tions of this session addressed the implementation of these
devices in the United States, their impact on PLT quality,
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the availability of PRT plasma in the United States, and the
health economic considerations.
Experiences from the nation’s largest blood product
supplier62 and the blood bank at the NIH Clinical Center63
were documented. Both reports stressed the relevance of
strict volume and cell limits, not required without PRT, and
their effect on collection procedures and failures. The
approaches were almost diametrically opposed, reﬂecting
the different donor settings: while the American Red Cross
preferred small-volume over large-volume kits (2/3 vs. 1/3),
the NIH Blood Bank exclusively used dual-storage kits. The
American Red Cross is boosting PRT PLTs to meet the
steadily increasing demand. The NIH Blood Bank has trans-
itioned to 100% PRT PLT production, which was well
received by the attending physicians and nurses.
Quality variables are expected to change, as PRT affects
all treated cells. The risks must be monitored and balanced
while the technologies for PRT and PLT additive solution
(PAS) continue to evolve.64 PRT plasma from individual
donors, although FDA-licensed devices are available, had not
been introduced in patient care by the end of 2018. Similar to
lyophilized plasma, which is not available from single-donor
sources,65 a PRT plasma alternative pooled from many donors
does exist: S/D-treated plasma66 has a history of worldwide
use since 1992. Five randomized controlled trials showed no
difference in efﬁcacy, but trial sizes ranged from 49 to
293 patients for a total of only 552 patients. No TRALI has
been reported from passively collected data, which may not
reﬂect all incidence.
Cost-effectiveness estimates for PRT PLTs and plasma
were reported.67 These products are considered no less cost-
effective than other widely adopted interventions in the con-
text of blood safety technologies. A budget gap is likely to
remain until PRTs become available for WB or RBCs. Low-
and middle-income countries may require a mixed approach
of needs assessment and targeted interventions.68 While PRT
PLTs have been implemented nationwide in some coun-
tries69 in an effort to improve patient safety, reimbursement
was noted as a key factor in the United States stalling the
quicker implementation of PRT PLT and plasma transfusions.
Experience implementing pathogen reduction
technology—David Angus Reeve, MBA, MHA
Speaker’s summary: Red Cross implemented PI technology
with the treatment of apheresis PLTs in March 2015. The
program was Initiated in Puerto Rico under a clinical study.
The organization initiated routine production of PR PLTs in
July 2016; it will have 15 manufacturing sites producing
pathogen inactivated products by early 2019.
Implementation challenges
The most signiﬁcant challenge with during the initial experi-
ence was that a limited percentage of PLT collections were
eligible for PI based on approved guard bands. There was
also a goal to do no harm to the PLT supply due to the
growing demand for single-donor PLTs by converting triples
to doubles or doubles to singles to qualify for PI. Finally, a
licensed INTERCEPT kit for PAS triples does not yet exist.
The initial performance against guard bands was unsat-
isfactory; more than 30% apheresis PLTs produced in Red
Cross are from triples leaving only doubles or singles to
qualify. Most of the single- and double-plateletpheresis
units failed to natively meet PI input requirements because
of targeted programing set points to maximize yield on col-
lections devices and the default values for ﬁrst-time donors.
Overcoming implementation challenges
Red Cross initiated evaluation of mitigation strategies
designed to increase percentage of units that qualify for
PI. Volume reduction was deployed by removing product vol-
ume from a homogenous mixture of Amicus-PAS apheresis
PLTs meet Intercept guard bands. Red Cross developed and
validated a software tool that aids staff in selecting options for
volume reduction.
Additional mitigations were developed in advance of
an INTERCEPT triple kit. Staff split triple collections into
three individual storage containers before PRT and use sin-
gle (small-volume or large-volume) INTERCEPT kits to treat
products individually. Large-volume doubles may be split
into two small-volume or large-volume kits; the collections
team adjusted Amicus settings to optimize storage volumes
to 625 mL for doubles and 780 mL for triples, which
included a minimum 10-mL volume buffer and a minimum
PLT yield of 3.4.
Results of mitigations
Approximately 65% of PLT products met the guard bands
during the operational trial. Presplitting largely obviated the
need for conducting volume reduction. The number of PR
units currently labeled is less than 50% due to combination
of demand, stafﬁng, aggregates, and units exceeding
24 hours. Additional observations included a radical shift in
type of PI kit used from predominantly dual-storage kits to
small-volume kits; the use of large-volume kits remained
the same. Before implementation of mitigations, the split
rate of PI products fell to 1.30. After implementation of miti-
gations the split rate of PI products increased to 2.10. Pro-
gramming of Amicus devices was standardized, and
collection volume increased; triples became eligible and
products were not downgraded.
The labor required for PRT is greater than using the
BacT/ALERT system with a single bottle. Time studies com-
pared both processes. Demonstrated an 11.1% increase in
the time required to complete tasks for unmitigated PI prod-
ucts as compared to the traditional process. There was a
22% increase in time required to complete tasks for miti-
gated PI products compared to traditional process. Produc-
tivity for the unmitigated PI process was poor because the
volume of products eligible for treatment was low with
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batch sizes of two to four products. Productivity improved
52% after implementation of mitigation steps due to signiﬁ-
cant increase in products eligible for treatment with
Increased batch sizes of eight to 12 products.
Conclusion
Pathogen reduction of 100% products is challenging but not
impossible based on current guard bands. Mitigations
required to meet guard bands are feasible but labor-
intensive and time-consuming. Implementation of PRT will
require adjustment of set points and collection variables on
apheresis devices.
Implementation in a hospital-based blood center
and acceptance by hospital staff—Willy Albert
Flegel, MD
Speaker’s summary: The NIH Clinical Center at the National
Institutes of Health is the nation’s largest hospital devoted
entirely to clinical research.63 Approximately 1600 studies
are in progress, focusing on Phase I and II clinical trials.
The Department of Transfusion Medicine is a full-service
blood bank providing blood donation, clinical apheresis,
transfusion service, human leukocyte antigen (HLA) and
infectious disease testing for the hospital, and cellular engi-
neering70 in support of cell therapies.71
In 2016, we transfused 3930 PLT, 4561 RBC, 614 plasma,
and 59 granulocyte products to 668 patients. All blood com-
ponents are 25 Gy irradiated; RBC products are also leuko-
reduced72,73 since 2009 and none is transfused older than
35 days74,75 since 2014. We transitioned to PR PLTs (100%
collected by apheresis) with PAS in January 2016.
Within 1 month of the device’s approval by the FDA,
the NIH Clinical Center decided in January 2015 to imple-
ment PRT76 and concurrently a PAS for all PLT products,
ﬁnally bringing this long-anticipated technology77,78 to the
bedside in the United States. A retrospective evaluation of
1007 successful collections during 6 months in early 2015
showed 99.7% of the collections that met any guard bands
speciﬁed by PRT fell within the guard band of the PRT dual-
storage kit. We decided to exclusively use this kit and pre-
pared to adjust the variables for approximately 5% of our
collections to meet the guard band speciﬁcations. If suc-
cessful, we anticipated a loss of less than 1% of collections
due to failures to meet the guard band.
Once agreements with the device providers were signed
(Intercept, Cerus Corporation; and Intersol, Fresenius Kabi),
the initial tasks of the implementation team involved writing
of validation plans and standard operating procedures;
ordering, installing, and validating required equipment; and
reconﬁguring space to house equipment and ﬁt the new work
ﬂow. Computer upgrades to accommodate changes were
made by July. Training for PRT began in August and for PAS
in September. Adjusting collection variables and validation of
PRT and PAS processes continued for the next 3 months.
The ﬁrst apheresis PLT product with PRT and PAS was
released on January 11, 2016. A dual inventory of PLTs pro-
duced by the new or the previous processes lasted for less
than 1 week, because we promptly transitioned all our PLT
collections to PRT and PAS. The ﬁne tuning of collection
variables was critical and needs to be monitored and
maintained continuously. This remains an ongoing task for
our donor staff during each PLT collection. We are closing
in on our original goal of less than 1% guard band failures
(Table 2) while producing 100% PRT PLTs from all plat-
eletpheresis collections at the NIH Clinical Center.
To bridge shortages of supply or serve patients with
rare HLA antibodies, we must import PLTs that remain
almost invariably produced without PRT. Their irradiation
with 25 Gy is required before they can enter the inventory
for release to patients. We do not provide bacterial testing
upon release and retired our previous precaution to prevent
bacterial contamination: 4 to 5 mL sampling within
24 hours of collection and release into inventory after
12 hours of negative culture in single standard aerobic bot-
tles (BACTEC, Becton, Dickinson and Co.) while monitoring
the culture for 7 days. With PRT products, the elimination
of irradiation (possible without variance notiﬁcation since
March 17, 2016)79 and bacterial culture resulted in substan-
tial savings of consumables and handling, which were how-
ever exceeded by the costs of the new technologies and the
increased hands-on time for the production staff. Reports of
transfusion reactions ranged from nine to 19 annually with-
out discernible trend, certainly no increase from 2015 to
2018; no severe transfusion reactions occurred.
Education and notiﬁcation are important for the accep-
tance by hospital staff. Within 2 weeks before the ﬁrst new
product was released for transfusion, we notiﬁed several
external customers and provided the revised circular of
information; there were no calls received. The prescribers
of the NIH Clinical Center were informed through the ofﬁce
of the deputy director for clinical care with a focus on
improved patient safety; there were a few calls. The nursing
staff was informed through the nursing education leader-
ship. We provided photos of current versus new bags,
highlighted the lack of irradiation labels for new bags only,
and explained the new electronic transfusion documenta-
tion. Some institutions are reluctant to introduce PRT PLTs
for neonates, children, and pregnant women because of the
theoretical risks associated with the toxicity of psoralen and
its photo products, for which there has been no evidence to
date in the doses applied. The few concerns raised at NIH,
for example, why the cost increase was justiﬁed, abated
once the ZIKV occurred in the continental United States
and PRT PLTs were recognized as safe without any action
needed.
Ongoing tasks are to improve the prompt availability of
predonation PLT counts to better control the collections
process and reduce guard band failures. We are optimizing
reports and documentation in pursuit of a biologics license
TRANSFUSION 7
PROCEEDINGS OF FDA WORKSHOP
application and FDA-CBER permission to eventually ship
the biologics product across state lines. Many patients
depend on PLT transfusions for their quality of life, and
PLTs with PRT and PAS enabled us to enhance patient
safety.80
Impact of pathogen reduction technology on
platelet quality, count, and clinical implications—
Dana V. Devine, PhD
Speaker’s summary: Laboratory investigations of PI-treated
PLT components readily show that the approaches used
generate changes to in vitro quality variables. This is an
expected result of PI as the treatments themselves are not
speciﬁc to pathogens and human cells are also targets.
Processing alone causes a loss of PLTs as the steps involve
transfer of the PLT concentrate to a treatment bag and
transfer back to storage bag in some cases. PLT count
reduction of 5% to 10% are typical, and production planning
must accommodate this loss.
Treated PLTs show evidence of activation,81–84 loss of
various RNA species,85,86 and an accelerated decrease in the
pH with storage.84 PI treatment may also cause the release
of PLT cytokines, including EGF, PDGF, and RANTES.87
Overall, the use of PI and/or reduction technologies
results in PLT responses that can be interpreted as a reduction
in PLT product quality in laboratory tests. It is unclear
whether we are using the best tests to perform quality moni-
toring of PR PLTs as they are the same as those used for
untreated PLTs.
Results of in vitro laboratory markers should not be pre-
sumed to parallel the clinical efﬁcacy of the PI-treated trans-
fusion product. PR PLTs show a 15% to 25% decrease in
survival and recovery in normal volunteers and, not surpris-
ingly, this translates into a shorter intertransfusion intervals
in patients receiving prophylactic transfusions with this prod-
uct.88,89 Unlike animal models, patients treated with PI PLTs
have an increased risk of alloimmunization for reasons yet to
be determined. Importantly, studies in hematologic oncology
patients do not reveal an increased risk of bleeding with the
use of PI-treated PLTs, although the use of AS may be a con-
founding factor.90–92 These differences compared to transfu-
sion with untreated PLTs are the tradeoff for increased safety.
There are still unknowns with respect to the use of PI-
treated PLTs in actively bleeding patients, particularly those
with massive hemorrhage.55 Whether use of large volumes
of PI-treated products, including PI-treated PLTs will
amplify the negative effect of PI on PLT efﬁcacy and overall
hemostasis remains to be determined. Limited retrospective
studies in surgical patients have not given cause for alarm
with respect to adverse reactions or efﬁcacy.32,93
Important research questions remain to be answered: 1)
Can we develop strategies to minimize damage to PLTs and
RBCs including the use of better ASs and storage conditions
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after treatment? 2) What are the best quality control measures
for PI PLTs? 3) Will the use of multiple types of PI-treated
products in trauma really create a problem? This needs to be
assessed clinically; however, such studies are expensive and
take a long time to complete. 4) Do we need to adapt transfu-
sion practice to accommodate PI-treated products? This may
be particularly important for pediatric patients. 5) How do we
best calculate the risk and beneﬁt of PI as it is an expensive
technology that may result in increased PLT use?
We must remind ourselves that PI for cellular products
is a major paradigm shift for transfusion safety. The systems
currently available are the ﬁrst generation and we will cer-
tainly see improvements over time that minimize the nega-
tive side of the balance sheet.
Using solvent/detergent-treated pooled plasma
(Octaplas): implementation at University of
Minnesota—Claudia Cohn, MD, PhD
Speaker’s summary: Octaplas, an FDA-approved blood com-
ponent, is S/D-treated plasma that is manufactured by com-
bining multiple ABO-matched plasma units from healthy US
donors. The plasma units, which are frozen within 8 hours
of collection, are pooled (approx. 380 L from 630 to 1520
donors in the United States) and then ﬁltered to remove
residual cells and treated with a combination of 1% tri(n-
butyl)-phosphate and 1% octoxynol to inactivate enveloped
viruses. The residual S/D is removed by oil extraction
and chromatography. The ﬁnal product is sterile-ﬁltered,
aliquoted into 200-mL bags, and stored frozen.94
Octaplas is indicated for replacement of coagulation fac-
tors in patients with acquired deﬁciencies due to liver disease
or undergoing cardiac surgery or liver transplant and for
plasma exchange in patients with thrombotic thrombocytope-
nic purpura. Octaplas is contraindicated in patients with
immunoglobulin A deﬁciency and severe deﬁciency of
protein S. All other contraindications, including a history of
hypersensitivity to fresh-frozen plasma and/or plasma-derived
products, are common to conventional plasma components.
Octaplas may be stored for up to three years at not more than
− 18C. After thawing, Octaplas may be stored for 24 hours at
+1 to 6C or for 8 hours at room temperature.
All plasma used to make Octaplas is tested for viral
markers in compliance with US regulation; however, addi-
tional steps further mitigate the risk of infectious disease
transmission. The S/D treatment inactivates enveloped
viruses with a log-kill reduction factor of at least 5 to 6 for
common viruses such as HIV, HBV and HCVC, WNV, ZIKV,
and Dengue virus. Additional testing is performed for nonen-
veloped viruses, so that the pooled plasma may not contain
more than 10.0 IU/μL parvovirus B19 DNA and must be neg-
ative for hepatitis A virus (HAV) by NAT polymerase chain
reaction (PCR) and hepatitis E virus (HEV) RNA by NAT PCR
(sensitivity of ≤2.5 log IU/mL). Furthermore, Octaplas con-
tains prespeciﬁed levels of neutralizing antibodies for HAV
and parvovirus B19. The ﬁnal sterile ﬁltration step (0.2 μm)
could remove additional infectious agents.
Pooling has the added beneﬁt of diluting allergens by
approximately 1000-fold, which reduces the risk of allergic
reactions. Multiple studies have shown a comparative reduc-
tion in the rate of allergic reactions (Table 3).95–101 Pooling
likely mitigates the risk of TRALI by diluting and neutralizing
antibodies to human neutrophil antigen and HLA. The S/D
process also removes bioactive lipids, which have been impli-
cated as a causative factor in TRALI. While proving a negative
is impossible, there have been more than 10 million units of
Octaplas transfused with zero incidence of TRALI reported.59
The levels of coagulation factors, protease inhibitors,
and cofactors are tested for each lot before release. Older
versions of S/D plasma were associated with hyper-
ﬁbrinolysis and bleeding;102–104 however, changes to the
manufacturing process have mitigated the risk of these
adverse events.105 In several studies conducted with the cur-
rent version of Octaplas, no additional risk of these or other
adverse events was identiﬁed.96,105–110 No clinically relevant
differences in efﬁcacy were identiﬁed; however, most of
these studies were small and may not have been powered
to show signiﬁcant differences.96,105–111
The University of Minnesota has chosen to maintain an
inventory of Octaplas for patients who have a history of mod-
erate to severe allergic transfusion reactions. It is especially
helpful for patients who are undergoing plasma exchange, as
they must contend with multiple units of conventional plasma.
The extra time and effort saved by the reduction of reactions
plus the increased comfort and safety experienced by the
patient make the added cost of Octaplas worthwhile. In con-
clusion, the efﬁcacy and safety proﬁles of Octaplas make it a
good alternative to conventional plasma, and it is beneﬁcial for
patients with a history of allergic transfusion reactions.
Health economic considerations for pathogen
reduction technology—Brian Custer, MPH, PhD
Speaker’s summary: Pathogen reduction technologies
must be evaluated with two different health economic
TABLE 3. A comparison of allergic reaction rates for
S/D versus conventional plasma
S/D plasma
Conventional
plasma
Study
author
Allergic
reactions/patients (%)
0/36 (0%) 0/31 (0%) Haubelt3
1/81 (1.2%) NA Solheim5
16/509 (3.1%) 16/172 (9.3%) Scully4
7/81 (8.6%) 8/27 (29.6%) Toussaint-Hacquard6
20/981 (2.0%) NA Vendramin7
1/35 (0.3%) NA Witt*8
Allergic reactions/10,000
transfusions
4.86 7.14 Bost2
* Pediatric patients.
TRANSFUSION 9
PROCEEDINGS OF FDA WORKSHOP
considerations in mind: effect on available ﬁnances or bud-
gets (budget impact analysis [BIA]) and an assessment of
value for money (CE analysis [CEA]).112 BIA is a type of cost
accounting study focused on implementation or mainte-
nance of a health care intervention over a relatively short
period of time, typically 1 to 5 years. CEA is an assessment
of the ratio of costs to beneﬁts, comparing at least two dif-
ferent interventions.113 Results are often reported as cost
per quality-adjusted life-year (QALY). The CE plane can be
used to graphically display the results for CEA separately for
costs and effects in a way that provides several insights into
the relative efﬁciency of each of the interventions included
in the analysis and thus is highly informative to the broader
decision making process for PRT.114
The health economics of PRT in the United States
continues to be one of the barriers to broader adoption.
For PRT there are several technologies, each with different
mechanisms of action and inactivation capacity, which
have been reviewed in detail in several previous
publications.26,27,58,115–118 These differences are important
for the health economics of each technology. Although
RBC inactivation and WB inactivation technologies are
in development119–122 and clinical studies are under
way,121,123 current health economic evidence has not been
published for these methods. Only two PRTs, S/D-treated
plasma, and amotosalen plus UV light for PLTs and
plasma are approved for use in the United States.
Budget impact
An exemplary combined BIA and CEA conducted by the
Canadian Agency for Drugs and Technologies in Health has
been reported.124 However, the health economics of PLT
PRT are arguably more important to deﬁne because BIA
and CEA for PLTs are highly dependent on the level of clini-
cally apparent bacterial contamination and PLT preparation
method in use in a given setting. A recently published BIA
focused on an analysis for a mid-sized US hospital that was
assumed to acquire 5500 apheresis PLT components per
year from an external blood supplier. Several assumptions
of this analysis sought to mimic a realistic situation: it was
assumed that approximately 60% of acquired PLTs are irra-
diated and 20% are tested for CMV by the blood supplier.
The model predicted minimal cost increase for PRT com-
pared to conventional PLTs after including cost offsets such
as elimination of bacterial detection and irradiation and dif-
ferential reimbursement for treated and untreated PLTs.38
Another BIA conducted for Italy concluded further studies
based on actual numbers of PLT transfusion complications
and their societal cost at a local level are needed to establish
the full cost to beneﬁt ratio of PLT PRT.125
CE
Several studies have examined the cost-effectiveness of
plasma PRT. Compared to a benchmark of $50,000 to
$100,000/QALY in most of health care, CE results for plasma
PRT are expected to fall in the range of $800,000 to
$1,200,000/QALY regardless of the technology. CE of PLT
PRT is more variable. Without removal of bacterial culture
and using hemovigilance data, estimates of $750,000 to
$1,000,000/QALY have been reported. If all bacterial con-
tamination, whether leading to clinically apparent sepsis is
considered and culture is discontinued, results might
approach $250,000/QALY. CE of PRT for both PLTs and
plasma if in addition to current interventions is estimated to
be approximately $1,250,000/QALY. The cost offsets that
might be feasible by discontinuing other interventions in
use alongside the cost of implementation need to be consid-
ered jointly as part of the value proposition of PRT.
Emerging agents will potentially shift ratios to being
more cost-effective but may not approach accepted thresh-
olds in health care. Analyses focused on the cost offsets that
can be achieved are being published and are expected to
increase in the near future.37,126 Reimbursement is also a
barrier to adoption. Assessment of budget impact, CE, and
pathways to reimbursement PRT are necessary consider-
ations for successful widespread use of PRT.
SESSION 3. PATHOGEN REDUCTION
TECHNOLOGIES FOR WHOLE BLOOD AND
RED BLOOD CELLS
Introduction. Moderator—Raymond
P. Goodrich, PhD
Technologies for the treatment of blood products to prevent
TT of diseases have been in development now for more
than 30 years.127 A review of the issues associated with
these technologies can now be considered from more than
a hypothetical framework and rather in the context of the
experiences and observations from their use in routine pro-
duction of PLT and plasma products.128 Such knowledge
may also be extrapolated to the ongoing development
efforts on methods for the treatment of WB or RBC prod-
ucts, which was the main topic for presentations in this
section of the workshop.
Recent developments have focused on the use of PRT
methods or modiﬁed methods using non–light-activated
chemistry, to treat either WB or the RBC component sepa-
rated from WB. Several of these products are in clinical
phases of evaluation. The challenges faced are expected to
be comparable to those experienced for the now broadly
approved and implemented methods for treating PLTs and
plasma with added complications and challenges due to the
number of units required to be treated and the nature of
the patients who receive RBC products compared to PLT
and plasma components. This session was intended to dis-
cuss some of the historical experience with PRT methods
and to provide an overview on the latest information avail-
able from the development of methods to produce WB or
RBC products treated with PRT methods.
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Optimal pathogen reduction system for blood
safety: is it a dream?—Raymond P. Goodrich, PhD.,
Colorado State University, CO
Speaker’s summary: Experience from the implementation of
PRT methods for PLTs and plasma has lessons to teach us
as we extend the application of these processes into the pro-
duction of WB and RBC products.
There will be a measurable reduction in cell or protein
quality after treatment
Preclinical studies and clinical trials with PRTs conducted in
the preceding 18 years have repeatedly demonstrated changes
in both in vitro and in vivo variables.129 These include
changes in metabolic variables in treated PLTs, changes in
aggregation, and adhesion function and changes in PLT prote-
omic and metabolomics measurements.130 Similar results
with plasma products have shown reduced coagulation factor
levels after treatment.131 Clinical studies evaluating the perfor-
mance of these products have demonstrated noninferiority
with regard to prevention of bleeding in patients with hemato-
logic malignancies. Estcourt and colleagues, summarizing
meta-analyses for 12 clinical trials with these products, indi-
cated that “We found moderate-quality evidence that
pathogen-reduced platelet transfusions do not affect all-cause
mortality, the risk of clinically signiﬁcant or severe bleeding,
or the risk of a serious adverse event.”132,133 The authors also
noted that, “We found high-quality evidence that pathogen-
reduced platelet transfusions increase the risk of platelet
refractoriness and the platelet transfusion requirement.”132,133
Additives will be added to the blood supply that are
not common blood additives or routinely present in the
human body
Most PRT methods that have been implemented and are
approved for use in the United States and outside the
United States are based on the use of chemical additives to
the blood products, which can be activated in speciﬁc ways
to prevent nucleic acid replication of targeted pathogens
and white blood cells (WBCs) in these products.25 The
nature of the compounds used in these approaches varies
considerably based on method and include the use of ribo-
ﬂavin134 and vitamin B2 as well as synthetically derived
compounds such as amotosalen and amustaline, which are
based on psoralen, acridine, and mustard hydrochloride
derivatives, respectively.135 In many cases, these agents and
their breakdown products exhibit considerable toxicity and
genotoxicity that must be considered in terms of likely
patient population and effectiveness of both handling and
removal methods intended to reduce exposure to patients
and health care workers.136 Processing requirements neces-
sitated by the nature of the agents used have complicated
the practical logistics of delivering blood products to
patients.118
Not all pathogens will be eliminated by the application
of these processes
Variable levels of PR are observed for bacteria and enveloped
viruses depending on the method that is being applied.137
Knowledge about what levels of inactivation are necessary to
prevent disease transmission are not clear or uniform for all
agents.138,139 Examples are now available from completed
and ongoing routine use studies that suggest that while dis-
ease transmission may be signiﬁcantly curtailed, some break-
through events may still be anticipated including cases where
pathogen loads in donated products may exceed inactivation
potential123 or where the PRT method may prove ineffective
against speciﬁc types of resistant agents such as nonen-
veloped viruses.140 Not all methods will deliver the same out-
comes in pathogen load reduction capabilities; hence
continued ﬁeld evaluation of what is needed to signiﬁcantly
reduce the probability of disease transmission in areas where
such diseases are endemic will be necessary to fully deter-
mine the extent of effectiveness.131
Process control will be essential to assure
reproducibility and reliability of these methods
Signiﬁcant efforts have been made by manufacturers to
develop techniques that can be practically applied to treat-
ment of PLT and plasma products in the routine blood bank
setting. Such devices and processes need to account for
practical factors including throughput, product speciﬁca-
tions, media, product losses, timing of process steps, record
keeping, and costs to manufacture disposables and equip-
ment. Validation of these methods has required signiﬁcant
investment on the part of manufacturers yet concerns in
each of these categories related to implementation remain
and continue to be identiﬁed as these methods enter rou-
tine clinical use.142
These processes will add cost
Routine implementation in high-income countries where
endemic disease and exposure are rare is likely to continue
to be debated on the basis of cost and beneﬁt. Advances in
adoption are likely to result when these processes can serve
low-income nations with signiﬁcant blood safety concerns
with affordable products made with high quality and low
cost. Questions about implementation with patients who are
most vulnerable and thus may beneﬁt the most from these
methods need to be asked. Such groups may include those
receiving chronic transfusion support or pediatric patients
where cost–beneﬁt and risk–beneﬁt calculations are likely to
have their most favorable outcomes.143 Providing products
to regions with high endemic disease rates can greatly
improve cost–beneﬁt analyses but will require partnerships
with nongovernmental organizations and longer-term con-
siderations of sustainability in these environments when
supplementation of costs is no longer feasible.144
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Clinical experience with pathogen reduction for red
blood cells: completing the triad—Richard
J. Benjamin, MD, PhD, FRCPath
Speaker’s summary: Unique technologies are needed to ade-
quately balance the need for robust, broad-spectrum PI and
the disparate characteristics of RBCs, PLTs, and plasma pro-
teins. INTERCEPT RBCs incorporate treatment of RBCs in
AS with 0.2 mmol/L amustaline (S-303) in the presence
of 20 mmol/L glutathione (GSH), in a closed system.135
Amustaline rapidly crosslinks and/or forms adducts with
nucleic acids to prevent pathogen replication without generat-
ing reactive oxygen species (ROS), while the active compound
degrades to undetectable concentrations (<0.75 nmol/L) dur-
ing processing. An exchange step into a licensed storage solu-
tion removes the majority of the breakdown products,
resulting in treated RBCs with a 35-day shelf life.145 Extensive
testing conﬁrmed a lack of neonatal and reproductive toxicity,
carcinogenicity, genotoxicity, and acute and chronic toxicity,
while conﬁrming potent inactivation of a broad range of
enveloped and nonenveloped viruses, bacteria, protozoa, and
WBCs.146 Animal models conﬁrmed a lack of immunogenicity.
Treated RBCs demonstrate reduced hemolysis and increased
ATP levels compared to conventional irradiated RBCs. A simi-
lar closed-system process is in development for WB collec-
tions in collaboration with the Swiss Red Cross for use in
austere environments.147
INTERCEPT RBCs were successfully evaluated in a series
of clinical trials demonstrating the safety, efﬁcacy, and the
performance of the system (Table 4). Radiolabeled recovery
and survival studies in healthy volunteers conﬁrm acceptable
RBC recovery and life span, exceeding FDA require-
ments.120,148 A Phase III randomized controlled study
(STARS) involving 51 complex cardiac surgery patients in
Germany demonstrated that treated RBCs met the
predetermined noninferiority margin for hemoglobin
(Hb) content (mean treatment difference [test–control] of
2.27 g/unit [95% CI, −2.61 to −1.92 g/unit), within the
prespeciﬁed equivalence margins (5 g/unit) and with
reduced hemolysis at the end of storage.149 Subjects received
a mean of 2.9 (range, 1-8) test or control RBC components
during surgery or within 7 days of surgery. Exploratory clini-
cal endpoints, including renal and hepatic insufﬁciency and
the 6-minute walk test, as well as adverse events, were not
different, and no patients had antibodies speciﬁc for
INTERCEPT RBCs.
A second randomized, double-blind, controlled cross-
over study (SPARC) performed in Italy and Turkey was com-
pleted in 81 transfusion-dependent thalassemia patients
who receive regular RBC transfusions to treat anemia and
suppress ineffective hematopoiesis (Table 4). Each patient
(≥10 years old) received six cycles (two “wash-in” and four
“efﬁcacy evaluation” cycles) of test and control RBCs with
the RBC dose determined by a physician blinded to treat-
ment. The primary endpoint was Hb consumption
(g Hb/kg/day), a measure of iron burden. Subjects met the
predetermined noninferiority margin of 15% of control for
Hb consumption in both the intention to treat and per-
protocol populations, receiving a mean of 12.6 test and con-
trol RBCs in the two treatment periods. Only 11 of 2006
(0.5%) RBC components were transfused off protocol to six
patients. Adverse events were similarly distributed between
periods, and no patients made treatment-emergent anti-
bodies to INTERCEPT RBCs or to RBC alloantigens.
The completed studies demonstrated the safety and
efﬁcacy of INTERCEPT RBCs while in vitro analyses demon-
strated robust PI. Further US clinical studies in cardiac sur-
gery (ReCePI) and in the general hospital population
(RedeS) are under way (see ClinicalTrials.gov). The avail-
ability of PRTs for RBCs, PLTs, and plasma would increase
patient safety and revolutionize the current reactive, incre-
mental testing approach to infectious disease threats. It may
also allow a reassessment of the need for current donor
deferral and testing requirements.
State of PRT for whole blood—Anna Razatos, PhD
Speaker’s summary: The Mirasol PRT system is CE marked
for the treatment of PLTs, plasma, and WB for transfusion and
is in routine use in many countries outside of the United
States. The Mirasol PRT system uses one device to treat all
blood products. Mirasol consists of the photosensitizer ribo-
ﬂavin (vitamin B2) in combination with UV light to irreversibly
damage DNA and RNA resulting in inactivation of viruses,
bacteria, parasites, and WBCs. Because riboﬂavin and its pho-
toproducts are nontoxic and naturally occurring, they do not
require removal from the blood product after treatment.
The WB Mirasol program has been developed in part-
nership with the US Department of Defense (DOD). The Afri-
can Investigation of Mirasol System (AIMS) clinical trial at
the Komfo Anokye Teaching Hospital in Kumasi, Ghana, is
the ﬁrst and only clinical trial to demonstrate that PRT can
effectively reduce the incidence of TTI of a blood-borne path-
ogen. The test arm consisted of Mirasol-treated non-
leukoreduced WB and the control arm consisted of untreated
nonleukoreduced WB.123 Sixty-ﬁve nonparasitemic patients
were exposed to parasitemic blood; 28 received Mirasol-
treated WB and 37 received untreated WB.123 The incidence
of transfusion-transmitted malaria was signiﬁcantly lower for
the patients receiving Mirasol-treated WB (one [4%] of
28 patients) compared to patients receiving untreated WB
(eight [22%] of 37 patients; p = 0039).123 Moreover there
were no signiﬁcant differences in 1) total Hb for up to
28 days posttransfusion and 2) adverse events between
Mirasol-treated WB and untreated WB.123 The success of the
AIMS clinical trial supported CE mark of the Mirasol PRT sys-
tem for the treatment of WB for transfusion.
After completion of the AIMS clinical trial, the Japan
International Cooperation Agency partnered with the Ter-
umo Corporation of Japan and the AABB Consulting
Services to support sustainable blood safety in Ghana with
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routine use of the Mirasol WB system in conjunction with
the creation of the infrastructure for a hemovigilance sys-
tem.150 The partnership expanded the use of Mirasol PRT
for WB within Ghana; established an active hemovigilance
system at two teaching hospitals, Komfo Anokye Teaching
Hospital in Kumasi and Korle-bu Teaching Hospital in
Accra; and provided the necessary training and support. In
September of 2018, Japan International Cooperation Agency
successfully handed over the Ghana Blood Safety Program
to the Ministry of Health (MOH).150
Dr. Aaron Tobian with the Makerere University–Johns
Hopkins University (MU-JHU) Collaboration will expand use
of the Mirasol PRT system for WB in Africa to Uganda with
the Mirasol Evaluation of Reduction in Infections Trial
(MERIT).141 The primary objective was to evaluate the Mir-
asol WB system to reduce malaria and other TTIs in
Uganda.150 Secondary objectives include an evaluation of
the impact of TTI and potential beneﬁt of PRT as well as the
feasibility and sustainability of implementing Mirasol in aus-
tere environments.141
In addition to Mirasol PRT treatment of WB for transfu-
sion, active studies are under way to evaluate compo-
nentization of Mirasol-treated WB. Terumo BCT has initiated
the PRAISE clinical trial to evaluate efﬁcacy and safety of RBCs
TABLE 4. Summary of completed clinical studies with INTERCEPT RBCs
Study161–163 Population Intervention Study design Comparison Outcome
CLI 00062 28 enrolled, 26
evaluable,
healthy
subjects
Compare survival
and recovery of
autologous
INTERCEPT RBCs
to conventional
RBCs (prototype
set)
Single-blinded,
randomized
crossover,
controlled
radiolabeled
autologous
RBC
Single transfusion
~10 mL of
51Cr-labeled
test or control
RBCs (35-day
storage)
RBCs prepared using the
INTERCEPT PI process were
physiologically and metabolically
suitable for transfusion after
35 days of storage, met the FDA
guidance criteria for 24-hour
recovery, and did not induce
antibody formation.
CLI 00073 42 enrolled, 26
evaluable,
healthy
subjects
Compare survival
and recovery of
autologous
INTERCEPT RBCs
to conventional
RBCs (ﬁnal set)
Single-blinded,
randomized
crossover,
controlled,
radiolabeled
autologous
RBC
Single transfusion
10-30 mL of
autologous
51Cr-labeled
test or control
RBCs (35-day
storage)
RBCs met the FDA criteria for
posttransfusion RBC recovery
24 hr after transfusion. The mean
life span and median life span
(T50) of autologous RBCs after
storage for 35 days were shorter
for test RBCs compared to
control RBCs, but within the
published reference range, and
the AUCs of test and control were
not different.
CLI 00070
(STARS)
87 randomized,
51 evaluable,
cardiac surgery
patients
Assess the in vitro
characteristics of
INTERCEPT
RBCs; assess the
clinical safety and
efﬁcacy of
INTERCEPT RBCs
in transfusion
support for acute
anemia
Randomized,
controlled,
double-blinded,
parallel design,
noninferiority
INTERCEPT or
conventional
RBCs for up to
7 days during
and after
surgery
The mean postproduction Hb
content per component was
53.6  5.6 g/component in the
test and 56.3  6.0 g/component
in the control groups.
Equivalence was declared since
the 95% CI for the mean
treatment difference was within
the a priori deﬁned margins
(5 g/component). INTERCEPT
RBC components met EDQM
guidelines for Hb content,
hematocrit, and hemolysis. The
safety proﬁle of INTERCEPT
RBCs was comparable to
conventional RBCs.
CLI 00076
(SPARC)
86 randomized,
81 evaluable,
transfusion-
dependent
thalassemia
patients
Evaluate the efﬁcacy
and safety of
INTERCEPT RBCs
in subjects who
require chronic
transfusion support
due to thalassemia
major
Randomized,
controlled,
double blinded,
two-period,
crossover,
noninferiority
Six transfusion
episodes of
INTERCEPT or
conventional
RBC; two
wash-in and
four evaluable
episodes
Mean Hb consumption (g/kg/day)
with INTERCEPT RBCs was not
inferior (p < 0.001) to
conventional RBCs (0.113  0.04
vs. 0.111  0.04, p = 0.373) by
intent-to-treat or per-protocol
(0.112  0.04 vs. 0.110  0.03,
p = 0.162) analysis. No
antibodies speciﬁc to
INTERCEPT RBCs were
detected; there were no
substantial differences in
transfusion reactions, adverse
events, or serious adverse events
recorded.
TRANSFUSION 13
PROCEEDINGS OF FDA WORKSHOP
derived from Mirasol-treated WB compared to conventional
RBCs in patients requiring chronic transfusion support.151
Moreover, Terumo BCT has supported investigator-initiated
studies of components derived from Mirasol-treated WB. One
such study conducted by Dr. Pavel Trakhtman from the
Russian Federal Center for Pediatric Hematology, Oncology
and Immunology evaluated the safety and efﬁcacy of RBCs
derived from Mirasol-treated WB in pediatric patients with
malignancies.152 Finally, as part of Terumo BCT’s commit-
ment to advancing blood safety, the company is investing in
innovation to further reﬁne and improve PRT.
Pathogen reduction technologies for red blood cell
products: impact on biochemical and viability
variables in humans—Jose A. Cancelas, MD, PhD
Speaker’s summary: Despite the implementation of im-
proved diagnostic screening and donor selection, the resid-
ual risk of transmission of new emerging pathogens and
bacterial contamination persists. PR of blood components
may be capable of proactively reducing and/or eliminating
the chance of disease transmission by transfusion. PR could
replace the current paradigm of serial introduction of diag-
nostic tests as new microorganisms with potential TT are
recognized. PR for RBC and WB products remains a major
challenge in the development of safe blood products for
transfusion and it is of major interest in the context of
chronic transfusion protocols.
The ﬁrst technology evaluated was the use of ribo-
ﬂavin/UV (80 J/mL RBC) light (Mirasol) system for PR of
WB. The riboﬂavin/UV light PR technology (Mirasol PRT sys-
tem, or Mirasol) method is based on irreversible nucleic acid
damage mediated by electron transfer processes at sites where
riboﬂavin-guanine base chemistry occurs.153,154 Our group
and others have already published signiﬁcant information on
the RBC viability of PR WB-derived RBCs in vitro in the
context of high-dose illumination resulting in signiﬁcant
PR.84,154–164 These sets of data indicate that PR of WB is possi-
ble albeit at a loss of RBC viability in vitro as assessed by
hemolysis, ATP levels, and potassium leakage and in vivo as
assessed by 24-hour recovery and survival analyses.155,156
Through a two-center clinical trial, our combined data consis-
tently support that riboﬂavin/UV light–treated RBCs stored for
21 days after being generated from Mirasol-treated WB main-
tain adequate levels of 24-hour recovery as assessed by 51Cr-
tagged circulatory RBC survival analysis. As anticipated, there
was decreased in vivo viability of poststorage riboﬂavin/UV
light RBCs compared to data obtained from the same donors
similarly stored untreated RBCs. The overall 24-hour recovery,
survival, T50, and area under the curve (AUC) of Mirasol RBCs
were reduced by 9.9, 25.9, 36.9, and 16.5%, respectively, com-
pared to the subjects untreated control RBCs.165 As expected,
the percentage of RBC hemolysis signiﬁcantly correlated with
the 24-hour recoveries of the control RBCs but not with their
T50 survivals, suggesting that both hemolysis and 24-hour
recoveries measured the destruction of a population of cells
that did not survive storage. In contrast, there was no similar
correlation between percent hemolysis and recoveries of Mir-
asol RBCs nor between their T50 and percent hemolysis. How-
ever, for the Mirasol RBCs, there was a signiﬁcant correlation
between ATP levels and 24-hour recoveries, but a similar
association was not found for control RBCs.
The second technology tested was PRT using amustaline
(S-303). This approach to target nucleic acid–containing patho-
gens does not require photochemical activation through the use
of a small molecule (amustaline, S-303) that reacts rapidly with
nucleic acid and then decomposes into unreactive byproducts.
Published PI results show that amustaline treatment of RBCs
effectively inactivates multiple blood-borne pathogens (≥4 log)
and residual WBCs.147,166–169 To prevent nonspeciﬁc reactions
of amustaline with RBC membrane proteins, GSH is used in
conjunction with the amustaline treatment. In two different
two-center studies we analyzed the viability of RBCs prepared
with a second-generation process and stored for 35 days was
evaluated in two different blood centers in a Phase I and II clini-
cal trial design, respectively. Both were single-blind random-
ized, controlled, two-period crossover studies where amustaline
or control RBCs were prepared in random sequence and stored
for 35 days followed by 51Cr tagging and 24-hour RBC posttrans-
fusion recovery, mean life span, median lifespan (T50), and life
span AUC analyzed. The mean 24-hour posttransfusion recov-
ery of test and control RBCs was comparable (83.2%  5.2%
and 84.9%  5.9%, respectively; p = 0.06), and consistent with
the FDA criteria for acceptable RBC viability. There were differ-
ences in the T50 between test and control RBCs (33.5 and
39.7 days, 17% difference; p < 0.001) but it was within published
reference ranges of 28 to 35 days. The AUC (percent surviving ×
days) for test and control RBCs was similar (22.6 and 23.1% sur-
viving cells × days, respectively; p > 0.05). After infusion of test
RBCs, there were no clinically relevant abnormal laboratory
values or adverse events.
Both technologies represent examples of ﬁrst-generation
efforts toward developing a technology that can maintain the
product potency while eradicating nucleic acid–containing
pathogens. If the goal is to increase the safety with a tradeoff
of 10% reduction in RBC, the results provided indicate that
the potency of RBCs treated with both PR products, espe-
cially riboﬂavin/UV light, would fall short of such goal. I
believe that these results may form part of the basis for the
discussion on the development of improved protocols and/or
approaches to PR of WB in general and, speciﬁcally, RBCs.
SESSION 4: EMERGING INNOVATIONS
RELEVANT TO PATHOGEN REDUCTION
TECHNOLOGY AND ALTERNATIVES
Introduction. Moderator—Stephen J. Wagner, PhD
Most discussion in the conference was focused on the practice
of and issues surrounding current PR methods approved for
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use in the United States or Europe. Session 3 was devoted to
the development of emerging PRTs and alternatives to
PR. Use of different light sources for PR without the use of
photochemicals, as well as use of novel photochemicals or
photochemical mechanisms that target pathogens with less
collateral damage to the blood component, are emerging as
improvements to current methods of PR. Alternatively, differ-
ent storage conditions for components may reduce the poten-
tial for bacterial outgrowth in PLT components, reducing the
need for PR. Finally, PR of WB may produce sterile WB or iso-
lated components, simplifying PR compared to current
methods.
A nucleic acid–binding photosensitizer with ﬂexible
structure for pathogen inactivation in red blood cell
suspensions—Stephen J. Wagner, PhD
Speaker’s summary: Photochemicals localize at nucleic acid
target sites as well as off-target locations in the supernatant or
bound to RBCs or PLTs. Upon illumination, photochemicals
bound to target produce singlet oxygen or other ROS or are
involved with electron transfer and adduct formation,
preventing further replication of the pathogen. Photochemi-
cals localized in the supernatant can produce ROS, which can
diffuse to the PLT or RBC membrane to produce oxidative
damage or undergo electron transfer with other colocalized
photochemicals, producing photochemical dimers. Photo-
chemicals bound to the RBC or PLT membrane produce ROS,
which can oxidize membrane components or produce cova-
lent adducts to polyunsaturated lipids via electron transfer.170
Off-target lesions are responsible for alterations of in vitro or
in vivo properties of photochemically treated RBCs and PLTs.
Most photochemicals are composed of fused rings of
conjugated double bonds. When a photochemical absorbs
light, it cannot dissipate the absorbed energy via bond rota-
tion as heat because of the rigidity of the ring structure and
therefore releases energy via ﬂuorescence, phosphorescence,
or photochemical reactions. On the other hand, ﬂexible photo-
sensitizers can dissipate absorbed light energy through bond
rotation and, therefore, cannot readily act as a photochemical
unless rigidly bound to substrate in a planar geometry.
One such ﬂexible dye is thiazole orange, which binds
to the minor groove of nucleic acids and can act as a photo-
chemical when bound but does not participate in photo-
chemical reactions when free in solution.171 Use of
80 μmol/L thiazole orange in RBCs suspended in Erythrosol
AS and 7.9 J/cm2 cool white light resulted in inactivation of
more than 7 log vesicular stomatitis virus, more than 5.8 log
bovine virus diarrhea virus, 5.5 log pseudorabies virus, more
than 6.5 log extracellular HIV, more than 6.3 log intracellu-
lar HIV, more than 5 log of Leishmania donavani infantum,
and more than 5 log T. cruzi.171,172 Bacterial inactivation
ranged from 2.3 to more than 7 log, depending on the spe-
cies.171 RBC storage studies with thiazole orange demon-
strated a hemolysis of 0.43% on Day 42 compared to 0.1%
hemolysis of untreated controls, no change in ATP levels
during 42-day storage compared to untreated controls, and
a two- to threefold increase in potassium leakage in thiazole
orange–treated RBCs compared with untreated controls.
Unilluminated RBC controls containing thiazole orange had
0.3% hemolysis on Day 42, suggesting that some of the
observed hemolysis may be due to the presence of thiazole
orange rather than photo-induced hemolysis. Future devel-
opment of thiazole orange as a RBC photo-inactivating
agent will require toxicology, scale-up, and in vivo studies.
Blue light inactivation of pathogens in platelet and
plasma: a pilot study—Michelle Maclean, PhD
The antimicrobial properties of 405-nm violet-blue light is a
research area gaining increasing prominence, and due to
the inherent properties of these visible light wavelengths,
research has been initiated to investigate its potential for
development as a novel alternative PRT. The workshop pre-
sentation provided an overview of a pilot study that has
begun evaluation the antimicrobial capability and compati-
bility of 405-nm violet-blue light for decontamination of
blood transfusion components.
Recent studies have demonstrated the application of
violet-blue light for safe, continuous environmental decon-
tamination173 and its potential for wound decontamination.174
These antimicrobial applications are made possible due to the
safety advantages of these non–UV light wavelengths. Unlike
UV light, which induces direct DNA-based damage and/or
oxidative damage in exposed microbial cells (depending on
the exact UV wavelengths used), inactivation by violet-blue
light involves the excitation of endogenous photosensitive
porphyrin molecules found within exposed microbial cells.175
Although less germicidally efﬁcient, research has demon-
strated that these lower-energy violet-blue 405-nm photons
are particularly suited to decontamination of sensitive blood
components and have potential operational advantages. A
recent study176 demonstrated the antimicrobial potential of
405-nm light for decontamination of key bacterial pathogens
in blood plasma, with a complete 5-log reduction of Staphylo-
coccus aureus in plasma using a dose of approximately
360 J/cm2. Importantly, antiviral potential has also been dem-
onstrated in plasma, with a successful 5-log reduction of
calicivirus after a 561 J/cm2 light exposure.177 A major ﬁnding
demonstrated by the study4 was that the higher penetrability of
405-nm light photons facilitates decontamination of prebagged
transfusion products. Results showed signiﬁcant antimicrobial
efﬁcacy within sealed plasma transfusion bags, with approxi-
mately 99% inactivation of S. aureus contamination in plasma
achieved using low irradiance light at a dose of 144 J/cm2. Sim-
ilar antimicrobial results were presented demonstrating suc-
cessful decontamination of prebagged PLT suspensions, at
comparative dose levels to those used with plasma.
As with all PRTs, a crucial question that must be
answered is whether antimicrobial efﬁcacy can be imparted
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with negligible and/or minimal effect on the quality of the
blood component itself. Results of sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and Western blotting anal-
ysis were presented which highlighted the potential for “safe”
treatment of blood plasma and the need for determining
upper and lower threshold treatment levels, which would
facilitate decontamination while retaining plasma and PLT
integrity. With regard to PLTs, an evaluation of the in vivo
recovery of light-treated (10 mW/cm2 for 8 hr) PLTs in a
murine model demonstrated no difference to that of non-
treated PLTs. These results are encouraging; however, further
investigation is needed on the impact of dose delivery (high
irradiance light delivered over rapid exposure periods com-
pared to low irradiance light over longer exposures), as this
will inﬂuence the optimal treatment conditions for the blood
components. Discussions highlighted the potential for the
technology to be utilized for rapid treatment before storage
(for PLTs or plasma) or incorporation into standard storage
conditions for PLTs with the aim of extending the shelf life of
these sensitive components.
This ability to directly treat prebagged plasma and PLT
blood products using 405-nm light exposure, without the
addition of photosensitizer molecules, is highly desirable as
it would eliminate the requirement for the additional
processing stages needed with other PRTs for passage
through equipment and removal of chemical additives, thus
reducing cross-contamination risks and also potentially
reducing processing times. Thus, further research to expand
the understanding and compatibility of this technology with
blood transfusion products is warranted.
Pathogen reduction in blood products: refrigerate
and use pathogen reduction technology—COL
Andrew P. Cap, MD, PhD
The DOD has invested signiﬁcant resources into the devel-
opment of PRT to improve the safety of blood transfusion
on the battleﬁeld.178 In addition to the need to reduce the
risk of bacterial contamination associated with room tem-
perature storage of PLTs, the unique challenges of combat
casualty care include the need to collect WB and PLTs in
remote deployed environments and transfuse these prod-
ucts before the availability of transfusion-transmitted dis-
ease testing results. The risks inherent in these emergency
blood transfusions can be magniﬁed by donor exposure to
endemic diseases such as malaria and potentially to biowar-
fare agents. The possibility of myelosuppressive radiation
exposure on the battleﬁeld could require the inactivation of
WBCs in blood products to reduce the risk of TA-GVHD.
PRTs for WB and PLTs are urgently needed to support mili-
tary operations.
In addition to investing in technologies that use various
photosensitizers and UV light to damage nucleic acids in
pathogens and WBCs, the DOD has pursued alternative
blood storage approaches to not only reduce infectious risks
of transfusion but also increase the availability of PLTs,
since current room temperature storage practices limit shelf
life to 5 to 7 days. Refrigeration has been demonstrated to
signiﬁcantly reduce bacterial growth as well as reduce the
metabolic activity of PLTs during storage, preserving their
hemostatic function. Refrigerated PLTs retain signiﬁcant
capacity to adhere to collagen under shear, aggregate,
release granules, catalyze thrombin generation, and contract
clots for up to 21 days.179 Refrigeration causes partial activa-
tion of PLTs, leading to desialylation of membrane proteins
and clearance from circulation over 1-2 days in vivo.180 Nev-
ertheless, in a randomized trial in cardiac surgery patients,
refrigerated PLTs stored for up to 14 days performed com-
parably to standard-of-care PLTs stored for less than 7days
(K.M. Reddoch Cardenas and A. Cap, unpublished,
2019).181 PLTs can be refrigerated in either plasma or PAS,
and preliminary results suggest that PRT-treated PLTs can
also be refrigerated without loss of hemostatic func-
tion.182,183 Refrigeration thus offers not only an extra layer
of protection from bacterial pathogens in addition to PRT,
but also an opportunity to extend shelf life and availability
while preserving the essential contribution of PLTs to bleed-
ing control. It should be noted that refrigerated WB contains
active PLTs that have been shown to maintain considerable
hemostatic function through the entire shelf life of WB
(up to 35 days in CPDA-1).184,185
The DOD is also supporting the development of other
alternative storage modalities for PLTs such as cryopreser-
vation and lyophilization.178,186 Both technologies offer
extended storage times (years) and bacterial pathogen risk
reduction and could be combined with PRT. While the
clinical safety and efﬁcacy of these products is being
established, refrigeration with or without PRT offers a
practical way to improve PLT product safety and availabil-
ity. WB PRT remains an important capability gap for the
US military, but a technology using riboﬂavin and UV light
has been shown to yield a product with preserved hemo-
static function and to inactivate Ebola virus, among other
pathogens, and reduce transfusion-transmitted malaria;
this technology is in Phase III trials.123,184,187 Successful
development of WB PRT will be a landmark achievement
in the history of transfusion medicine and will beneﬁt
both civilian and military patients.
Concluding remarks. Insights for future research
and development—Paul Ness, MD
The comprehensive 2-day conference on PRTs organized by
the FDA presented the current state of the art and raised
several questions whose answers will drive future develop-
ment and clinical implementation of PRTs. Although the fol-
lowing list is by no means all-inclusive, it represents some
recurrent themes and areas that were considered during the
conference and that need to be addressed going forward as
issues of importance.
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Blood safety and pathogen kill
1. Do in vitro cell kill measures correlate with clinical efﬁ-
cacy? The reader is reminded that the AIMS trial in
Ghana showed malarial prevention with infectious loads
greater than the predicted capacity of the Mirasol sys-
tem123 and a review of this comprehensive topic has
been published in TRANSFUSION.139
2. What is the appropriate balance between pathogen kill
and blood component function?
PLT issues
1. Do PRT PLTs stop acute hemorrhage? Most of the clinical
trials have assessed prophylaxis to prevent hemorrhage in
patients with thrombocytopenia with hematologic
malignancies.
2. Can the damage to PLTs that occurs with available PRT
systems be mitigated to enhance PLT recovery, survival,
and function?
3. How effective are PRT PLTs in reducing alloimmunization?
Although leukoreduction has signiﬁcantly reduced
alloimmunization from 15% to 5% in patients with acute
leukemia, the problem of alloimmune refractoriness to
PLTs has not been eliminated.
4. Will PRT PLTs effectively reduce PLT transfusion reactions
involving WBCs such as febrile reactions and TRALI?
Plasma issues
1. What is the effect of PRT on procoagulant and pro-
thrombotic constituents and their balance in patients?
2. Can PRT be used to prepare pooled plasma products to
reduce infectivity risks while taking advantage of the abil-
ity of large pools of plasma to reduce transfusion compli-
cations such as allergic reactions, ABO antibody–induced
hemolysis, and hypocoagulability due to the variable
content of coagulation constituents in single bags?
3. Can recovered plasma containing additives required for
preparation of PRT treated WB be used in plasma
fractionation?
RBC issues
1. Can damage to RBCs with current PRT systems be lim-
ited by new processes under development or additional
manufacturing steps?
2. Do PRT processes affect immune-hematologic testing
procedures?
3. Does the addition of PRT reopen the age of blood storage
controversy?
Other unanswered questions
1. Do we really need blood storage for 42 days or could the
blood transfusion systems in the United States handle
shorter storage limited in required for PRT-treated RBCs?
2. Can FDA adopt guidelines for industry that would allow
enhancements in blood storage solutions using PRT to be
licensed and implemented that would be cost sensitive?
a. How much of the new knowledge about RBC storage
would need to be applied to applications for licensure
of PRT RBCs? Will recovery, survival, and hemolysis
be the major criteria for licensure?
b. Will FDA work with blood centers to increase efﬁcien-
cies with modiﬁed blood processing procedures and
elimination of redundant testing or donor history?
c. Will these cooperative efforts results in PRT compo-
nents that hospitals view as cost-effective and worthy
of the increased expenses?
d. If guidelines and requirements become too burden-
some, will we ever be able to take advantage the clinical
and operational advantages of PRT that will improve
patient care?
ACKNOWLEDGMENTS
The organizing committee thanks CBER Director Dr. Marks and
OBRR Director Dr. Verdun for their constant support and providing
direction to the committee. Dr. Flegel thanks Harvey Gordon Klein,
MD, for review of the manuscript and comments and acknowledges
the late Sherry Lynne Sheldon, MT(ASCP)SBB, whose contribution
as laboratory supervisor in the Laboratory Services Section was crit-
ical for efﬁciently implementing the technology in a timely manner
under ﬁscal constraints. PRT PLTs remain S.L. Sheldon’s legacy to
the patients and their safety at the NIH Clinical Center.
Dr. Benjamin acknowledges that INTERCEPT RBCs are being devel-
oped under contract with the Biomedical Advanced Research and
Development Authority, a division of the Department of Health and
Human Services.
CONFLICT OF INTEREST
SK is a consultant to Cerus, manufacturer of the Intercept system
and serves on Medical Advisory Board of Creative Testing Solutions
(CTS). ES is PI for the Cerus PIPER Phase IV clinical study at the Yale
site—he receives no personal remuneration. SR has nothing to dis-
close. WF states that the views expressed do not necessarily represent
the view of the National Institutes of Health, the Department of
Health and Human Services, or the US Federal Government and no
ﬁnancial relationship relevant for this publication. RB is an employee
and stockholder in Cerus Corporation, a manufacturer of pathogen
reduction technologies. AR is an employee of Terumo BCT.
REFERENCES
1. Perkins HA, Busch MP. Transfusion-associated infections:
50 years of relentless challenges and remarkable progress.
Transfusion 2010;50:2080-99.
2. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1
and HCV infections among antibody-negative blood donors by
nucleic acid-ampliﬁcation testing. N Engl J Med 2004;351:760-8.
3. Kleinman SH, Lelie N, Busch MP. Infectivity of human immu-
nodeﬁciency virus-1, hepatitis C virus, and hepatitis B virus
TRANSFUSION 17
PROCEEDINGS OF FDA WORKSHOP
and risk of transmission by transfusion. Transfusion 2009;49:
2454-89.
4. Busch MP, Bloch EM, Kleinman SH. Prevention of transfusion
transmitted infections. Blood. In press 2019;133:1854-64.
5. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious
disease agents and their potential threat to transfusion safety.
Transfusion 2009;49(Suppl 2):1S-29S.
6. Glynn SA, Busch MP, Dodd RY, et al. Emerging infectious
agents and the nation’s blood supply: responding to potential
threats in the 21st century. Transfusion 2013;53:438-54.
7. Atreya C, Nakhasi H, Mied P, et al. FDA workshop on emerg-
ing infectious diseases: evaluating emerging infectious dis-
eases (EIDs) for transfusion safety. Transfusion 2011;51:
1855-71.
8. Dodd R, Groves JA, Townsend RL, et al. Impact of one-time
testing for Trypanosoma cruzi antibodies among blood
donors in the United States. Transfusion 2019;59:1016-23.
9. Busch MP, Caglioti S, Robertson EF, et al. Screening the blood
supply for West Nile virus RNA by nucleic acid ampliﬁcation
testing. N Engl J Med 2005;353:460-7.
10. Dodd RY, Foster GA, Stramer SL. Keeping blood transfusion
safe from West Nile virus: American Red Cross Experience,
2003 to 2012. Transfus Med Rev 2015;29:153-61.
11. Williamson PC, Linnen JM, Kessler DA, et al. First cases of
Zika virus-infected US blood donors outside states with areas
of active transmission. Transfusion 2017;57(3pt2):770-8.
12. Saa P, Proctor M, Foster G, et al. Investigational testing for
Zika Virus among U.S. blood donors. N Engl J Med 2018;378:
1778-88.
13. Moritz ED, Winton CS, Tonnetti L, et al. Screening for Babesia
microti in the U.S. Blood Supply. N Engl J Med 2016;375:
2236-45.
14. Ward SJ, Stramer SL, Szczepiorkowski ZM. Assessing the risk
of Babesia to the United States blood supply using a risk-
based decision-making approach: Report of AABB’s Ad Hoc
Babesia Policy Working Group (original report). Transfusion
2018;58:1916-23.
15. Ramirez-Arcos S, DiFranco C, McIntyre T, et al. Residual risk
of bacterial contamination of platelets: six years of experience
with sterility testing. Transfusion 2017;57:2174-81.
16. Urwin PJ, Mackenzie JM, Llewelyn CA, et al. Creutzfeldt-Jakob
disease and blood transfusion: updated results of the UK
Transfusion Medicine Epidemiology Review Study. Vox Sang
2016;110:310-6.
17. Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an
infectious retrovirus, XMRV, in blood cells of patients with
chronic fatigue syndrome. Science 2009;326:585-9.
18. Simmons G, Glynn SA, Komaroff AL, et al. Failure to conﬁrm
XMRV/MLVs in the blood of patients with chronic fatigue
syndrome: a multi-laboratory study. Science 2011;334:814-7.
19. Bennett JL, Devine DV. Risk-based decision-making in trans-
fusion medicine. Vox Sang 2018;113:737-49.
20. Bloch EM, Ness PM, Tobian AAR, et al. Revisiting blood safety
practices given emerging data about Zika virus. N Engl J Med
2018;378:1837-41.
21. Center for Biologics Evaluation and Research. Bacterial risk con-
trol strategies for blood collection establishments and transfusion
services to enhance the safety and availability of platelets for
transfusion: draft guidance for industry [Internet]. Rockville (MD):
Food and Drug Administration; 2018 [cited 2019 Aug 05].
Available from: https://www.fda.gov/regulatory-information/
search-fda-guidance-documents/bacterial-risk-control-strategies-
blood-collection-establishments-and-transfusion-services-enhance.
22. Ceros Corporation. FDA approves pathogen reduction system
to treat platelets. [Press Release]. 2014. Available from: http:
//www.cerus.com/Investors/Press-Releases/Press-Release-
Details/2014/FDA-Approves-INTERCEPT-Blood-System-for-
Platelets/default.aspx.
23. US Food and Drug Administration. Summary of safety and effec-
tiveness data: INTERCEPT blood system for platelets. [Press
Release]. 2014. Available from: https://www.fda.gov/
downloads/BiologicsBloodVaccines/BloodBloodProducts/
ApprovedProducts/PremarketApprovalsPMAs/UCM431243.pdf.
24. Cerus Corporation. INTERCEPT Blood System for Platelets
[package insert]. Concord (CA): Cerus Corporation; 2015.
25. Mundt J, Rouse L, Van den Bossche J, et al. Chemical and
biological mechanisms of pathogen reduction technologies.
Photochem Photobiol 2014;90:957-64.
26. Schlenke P. Pathogen inactivation technologies for cellular blood
components: an update. Transfus Med Hemother 2014;41:309-25.
27. Seltam A. Pathogen inactivation of cellular blood products- an
additional safety layer in transfusion medicine. Front Med
(Lausanne) 2017;4:219.
28. Terumo BCT. Terumo BCT announces enrollment of the ﬁrst
patient in its U.S. clinical trial designed to study platelets
treated with the Mirasol® pathogen reduction technology
(PRT) system [Internet]. Lakewood (CO): Terumo BCT; 2017.
Available from: https://www.terumobct.com/Pages/News/
Press%20Releases/Terumo-BCT-Announces-Enrollment-of-
the-First-Patient--in-Its-U-S--Clinical-Trial-Designed-to-
Study-Platelets-Treated--With-.aspx.
29. Thiele T, Pohler P, Kohlmann T, et al. Tolerance of platelet
concentrates treated with UVC-light only for pathogen
reduction- a phase I clinical trial. Vox Sang 2015;109:44-51.
30. Jaquot C, Delaney M. Pathogen-inactivated blood products
for pediatric patients: blood safety, patient safety, or both?
Transfusion 2018;58:2095-101.
31. Amato M, Schennach H, Astl M, et al. Impact of platelet path-
ogen inactivation on blood component utilization and patient
safety in a large Austrian regional medical center. Vox Sang
2017;112:47-55.
32. Nussbaumer W, Amato M, Schennach H, et al. Patient out-
comes and amotosalen/UVA-treated platelet utilization in
massively transfused patients. Vox Sang 2017;112:249-56.
33. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active
haemovigilance study with combined cohort analysis of 19 175
transfusions of platelet components prepared with
amotosalen-UVA photochemical treatment. Swissmedic
Haemovigilance Annual Report 2014. Vox Sang 2015;109:
343-52.
18 TRANSFUSION
ATREYA ET AL.
34. Gokhale A, Schulz W, Bahar B, et al. Transfusion reaction
rates of pathogen reduced (PR) vs conventional (CONV)
platelets in adults: a single academic center experience.
Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/
doi/10.1111/trf.14903):6A-254A.
35. Gehrie E, Schulz W, Young P, et al. A retrospective evaluation
of the hemostatic efﬁcacy of pathogen reduced (PR) vs con-
ventional (CONV) platelets at an academic medical center.
Transfusion 2018;58(S2). https://onlinelibrary.wiley.com/
doi/10.1111/trf.14903):6A-254A.
36. Schulz W, Gokhale A, McPadden J, et al. Transfusion of path-
ogen reduced (PR) vs conventional (CONV) platelets in pedi-
atric patients: an assessment of platelet usage and incidence
of transfusion reactions. Transfusion 2018;58(S2). https:
//onlinelibrary.wiley.com/doi/10.1111/trf.14903):6A-254A.
37. McCullough J, Goldﬁnger D, Gorlin J, et al. Cost implications
of implementation of pathogen-inactivated platelets. Transfu-
sion 2015;55:2312-20.
38. Prioli K, Katz J, Lyons N, et al. Economic implications of path-
ogen reduced and bacterially tested platelet components: a
US hospital budget impact model. Appl Health Econ Health
Policy 2018;16:889-99.
39. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen
plasma prepared with amotosalen HCl (S-59) photochemical
pathogen inactivation: transfusion of patients with congenital
factor deﬁciencies. Transfusion 2005;45:1362-72.
40. Larrea L, Ortiz-de-Salazar M-I, Martinez P, et al. Quantitative
analysis of plasma proteins in whole-blood derived fresh fro-
zen plasma prepare with three pathogen reduction technolo-
gies. Transfus Apher Sci 2009;41:199-204.
41. Smith J, Rock G. Protein quality in Mirasol pathogen reduc-
tion technology-treated apheresis-derived fresh-frozen
plasma. Transfusion 2010;50:926-31.
42. Coene J, Devreese K, Sabot B, et al. Paired analysis of plasma
proteins and coagulation capacity after treatment with three
methods of pathogen reduction. Transfusion 2014;54:1321-31.
43. Hornsy VS, Drummond O, Morrison A, et al. Pathogen reduc-
tion of fresh plasma using riboﬂavin and ultraviolet light:
effects on plasma coagulation proteins. Transfusion 2009;49:
2167-72.
44. Theusinger OM, Goslings D, Studt J-D, et al. Quarantine ver-
sus pathogen-reduced plasma-coagulation factor content and
rotational thromboelastometry coagulation. Transfusion 2017;
57:637-45.
45. Irsch J, Pinkosky L, Corash L, et al. Intercept plasma: compa-
rability with conventional fresh-frozen plasma based on coag-
ulation function - an in vitro analysis. Vox Sang 2010;98:
47-55.
46. Solheim BG, Chetty R, Flesland O. Indications for use and
cost-effectiveness of pathogen-reduced ABO-universal
plasma. Curr Opin Hematol 2008;15:612-7.
47. Cid J, Caballo C, Pino M, et al. Quantitative and qualitative
analysis of coagulation factors in cryoprecipitate prepared
from fresh-frozen plasma inactivated with amotosalen and
ultraviolet A light. Transfusion 2013;53:600-5.
48. Ettinger A, Miklauz MM, Bihm DJ, et al. Preparation of
cryoprecipitate from riboﬂavin and UV-light treated plasma.
Transfus Apher Sci 2012;46:153-8.
49. Hubbard T, Backholer L, Wiltshire M, et al. Effect of riboﬂavin
and amotosalen photoactivation systems for pathogen inacti-
vation of fresh-frozen plasma on ﬁbrin clot structure. Transfu-
sion 2016;56:41-8.
50. Cinqualbre J, Kientz D, Remy E, et al. Comparative effective-
ness of plasma prepared with amotosalen-UVA pathogen
inactivation and conventional plasma for support of liver
transplantation. Transfusion 2015;55:1710-20.
51. Mintz PD, Neff A, MacKenzie M, et al. A randomized,
controlled Phase III trial of therapeutic plasma exchange
with fresh-frozen plasma (FFP) prepared with amotosalen
and ultraviolet A light compared to untreated FFP in throm-
botic thrombocytopenic purpura. Transfusion 2006;46:
1693-704.
52. Guignier C, Benamara A, Oriol P, et al. Amotosalen-
inactivated plasma is equally well tolerated as quarantine
plasma in patients undergoing large volume therapeutic
plasma exchange. Transfus Clin Biol 2018;25:73-7.
53. Haugaa H, Taraldsrud E, Nyrerød HC, et al. Low incidence of
hyperﬁbrinolysis and thromboembolism in 195 primary liver
transplantations transfused with solvent/detergent-treated
plasma. Clin Med Res 2014;12:27-32.
54. Yarranton H, Cohen H, Pavord SR, et al. Venous thrombo-
embolism associated with the management of acute throm-
botic thrombocytopenic purpura. Br J Haematol 2003;121:
778-85.
55. Hess JR, Pagano MB, Barbeau JD, et al. Will pathogen reduc-
tion of blood components harm more people than it helps in
developed countries. Transfusion 2016;56:1236-41.
56. Arbaeen AF, Schubert P, Serrano K, et al. Pathogen inactiva-
tion treatment of plasma and platelet concentrates and their
predicted functionality in massive transfusion protocols.
Transfusion 2017;57:1208-17.
57. Saadah NH, van Hout FMA, Schipperus NR, et al. Comparing
transfusion reaction rates for various plasma types: a system-
atic review and meta-analysis/regression. Transfusion 2017;
57:2104-14.
58. Solheim BG, Seghatchian J. Update on pathogen reduction
technology for therapeutic plasma: an overview. Transf Apher
Sci 2006;35:83-90.
59. Hellstern P, Solheim BG. The use of solvent/detergent treat-
ment in pathogen reduction of plamsa. Transf Med Hemother
2011;38:65-70.
60. Riedler GF, Haycox AR, Duggan AK, et al. Cost-effectiveness
of solvent/detergent-treated fresh-frozen plasma. Vox Sang
2003;85:88-95.
61. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of
solvent-detergent treated plasma. In search of a zero-risk
blood supply. JAMA 1994;272:1210-4.
62. Stramer SL, Dodd RY. Transfusion-transmitted emerging
infectious diseases: 30 years of challenges and progress.
Transfusion 2013;53:2375-83.
TRANSFUSION 19
PROCEEDINGS OF FDA WORKSHOP
63. Gallin JI. The NIH Clinical Center and the future of clinical
research. Nat Med 2011;17:1221-3.
64. Devine DV. Pathogen inactivation strategies to improve blood
safety: let’s not throw pathogen-reduced platelets out with
their bath water. JAMA Oncol 2018;4:458-9.
65. Booth GS, Lozier JN, Nghiem K, et al. Spray: single-donor
plasma product for room temperature storage. Transfusion
2012;52:828-33.
66. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-
treated plasma: a virus-inactivated substitute for fresh frozen
plasma. Blood 1992;79:826-31.
67. Custer B, Agapova M, Martinez RH. The cost-effectiveness of
pathogen reduction technology as assessed using a multiple
risk reduction model. Transfusion 2010;50:2461-73.
68. Custer B, Zou S, Glynn SA, et al. Addressing gaps in interna-
tional blood availability and transfusion safety in low- and
middle-income countries: a NHLBI workshop. Transfusion
2018;58:1307-17.
69. Jutzi M, Mansouri Taleghani B, Rueesch M, et al. Nationwide
implementation of pathogen inactivation for all platelet con-
centrates in Switzerland. Transfus Med Hemother 2018;45:
151-6.
70. Klein HG. Cellular gene therapy: an overview. J Clin Apher
1994;9:139-41.
71. Carter CS, Leitman SF, Cullis H, et al. Technical aspects of
lymphokine-activated killer cell production. J Clin Apher
1988;4:113-7.
72. Klein HG. Immunologic aspects of blood transfusion. Semin
Oncol 1994;21:16-20.
73. Willy C, Reithmeier W, Kuhlmann WD, et al. Leukocyte
depletion of red cell components prevents exposure of trans-
fusion recipients to neutrophil elastase. Vox Sang 2000;78:
19-27.
74. Klein H, Natanson C, Flegel W. Transfusion of fresh vs. older
red blood cells in the context of infection. ISBT Sci Ser 2015;
10:275-85.
75. Flegel WA, Natanson C, Klein HG. Does prolonged storage of
red blood cells cause harm? Br J Haematol 2014;165:3-16.
76. Lozano M, Cid J, Prowse C, et al. Pathogen inactivation or
pathogen reduction: proposal for standardization of nomen-
clature. Transfusion 2015;55:690.
77. Klein HG. Will blood transfusion ever be safe enough? JAMA
2000;284:238-40.
78. Klein HG, Glynn SA, Ness PM, et al. Research opportunities
for pathogen reduction/inactivation of blood components:
summary of an NHLBI workshop. Transfusion 2009;49:1262-8.
79. Regan D, Markowitz MA. Changes to the 30th edition of Stan-
dards for Blood Banks and Transfusion Services. AABB Asso-
ciation Bulletin 2016;#16-05:1-4.
80. Snyder EL, Stramer SL, Benjamin RJ. The safety of the
blood supply - time to raise the bar. N Engl J Med 2015;372:
1882-5.
81. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional
characteristics of S-59 photochemically treated platelet con-
centrates derived from buffy coat. Vox Sang 2000;76:209-14.
82. Johnson L, Loh YS, Kwok M, et al. In vitro assessment of
buffy-coat derived platelet components suspended in SSP+
treated with the INTERCEPT Blood system. Transfus Med
2013;23:121-9.
83. Picker SM, Speer R, Gathof BS. Functional characteristics of
buffy coat PLTs photochemically treated with amotosalen-HCl
for pathogen inactivation. Transfusion 2004;44:320-9.
84. Schubert P, Culibrk B, Karwal S, et al. Whole blood treated
with riboﬂavin and ultraviolet light: quality assessment of all
blood components produced by the buffy coat method.
Transfusion 2015;55:815-23.
85. Osman A, Hitzler WE, Meyer CU, et al. Effects of pathogen
reduction systems on platelet microRNAs, mRNAs, activation,
and function. Platelets 2015;26:154-63.
86. Klein-Bosgoed C, Schubert P, Devine DV. Riboﬂavin and
ultraviolet illumination affects selected platelet mRNA tran-
script amounts differently. Transfusion 2016;56:2286-95.
87. Schubert P, Culibrk B, Lautens B, et al. Increased cytokine
release from platelet concentrates following riboﬂavin/UV
light treatment accelerates endothelial cell proliferation and
migration. Transfusion 2013;53(suppl):S84-040A.
88. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion
of pooled buffy coat platelet components prepared with pho-
tochemical pathogen inactivation treatment: the euroSPRITE
trial. Blood 2003;101:2426-33.
89. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic
efﬁcacy and safety of platelets treated with a photochemical
process for pathogen inactivation: the SPRINT Trial. Blood
2004;104:1534-41.
90. Estcourt LJ, Malouf R, Murphy MF. Pathogen reduced plate-
lets for the prevention of bleeding in people of any age. JAMA
Oncol 2018;4:571-2.
91. Garban F, Guyard A, Labussière H, et al. Evaluation of the Efﬁ-
cacy of Platelets Treated With Pathogen Reduction Process
(EFFIPAP) Study Group. Comparison of the hemostatic efﬁcacy
of pathogen-reduced platelets vs untreated platelets in patients
with thrombocytopenia and malignant hematologic diseases: a
randomized clinical trial. JAMA Oncol 2018;4:468-75.
92. van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic
efﬁcacy of pathogen-inactivated vs untreated platelets: a ran-
domized controlled trial. Blood 2018;132:223-31.
93. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active
haemovigilance study with combined cohort analysis of
19,175 transfusions of platelet components prepared with
amotosalen-UVA photochemical treatment. Vox Sang 2015;
109:343-52.
94. Liumbruno GM, Marano G, Grazzini G, et al. Solvent/
detergent-treated plasma: a tale of 30 years of experience.
Expert Rev Hematol 2015;8:367-74.
95. Bost V, Odent-Malaure H, Chavarin P, et al. A regional
haemovigilance retrospective study of four types of therapeu-
tic plasma in a ten-year survey period in France. Vox Sang
2013;104:337-41.
96. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/
detergent-treated plasma and fresh-frozen plasma on
20 TRANSFUSION
ATREYA ET AL.
haemostasis and ﬁbrinolysis in complex coagulopathy follow-
ing open-heart surgery. Vox Sang 2002;82:9-14.
97. Scully M, Longair I, Flynn M, et al. Cryosupernatant and sol-
vent detergent fresh-frozen plasma (Octaplas) usage at a sin-
gle centre in acute thrombotic thrombocytopenic purpura.
Vox Sang 2007;93:154-8.
98. Solheim BG, Granov DA, Juravlev VA, et al. Universal fresh-
frozen plasma (Uniplas): an exploratory study in adult
patients undergoing elective liver resection. Vox Sang 2005;89:
19-26.
99. Toussaint-Hacquard M, Coppo P, Soudant M, et al. Type of
plasma preparation used for plasma exchange and clinical
outcome of adult patients with acquired idiopathic throm-
botic thrombocytopenic purpura: a French retrospective mul-
ticenter cohort study. Transfusion 2015;55:2445-51.
100. Vendramin C, McGuckin S, Alwan F, et al. A single-center
prospective study on the safety of plasma exchange proce-
dures using a double-viral-inactivated and prion-reduced
solvent/detergent fresh-frozen plasma as the replacement
ﬂuid in the treatment of thrombotic microangiopathy. Trans-
fusion 2017;57:131-6.
101. Witt V, Pichler H, Beiglboeck E, et al. Changes in hemostasis
caused by different replacement ﬂuids and outcome in
therapeutic plasma exchange in pediatric patients in a retro-
spective single center study. Transfus Apher Sci 2017;56:
59-65.
102. de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis
during liver transplantation is enhanced by using solvent/
detergent virus-inactivated plasma (ESDEP). Anesth Analg
2002;94:1127-31.
103. Magner JJ, Crowley KJ, Boylan JF. Fatal ﬁbrinolysis during
orthotopic liver transplantation in patients receiving solvent/
detergent-treated plasma (Octaplas). J Cardiothorac Vasc
Anesth 2007;21:410-3.
104. Heger A, Romisch J, Svae TE. A biochemical comparison of a
pharmaceutically licensed coagulation active plasma
(Octaplas) with a universally applicable development product
(Uniplas) and single-donor FFPs subjected to methylene-blue
dye and white-light treatment. Transfus Apher Sci 2006;35:
223-33.
105. Jilma-Stohlawetz P, Kursten FW, Horvath M, et al. Recovery,
safety, and tolerability of a solvent/detergent-treated and
prion-safeguarded transfusion plasma in a randomized, cross-
over, clinical trial in healthy volunteers. Transfusion 2013;53:
1906-17.
106. Bartelmaos T, Chabanel A, Leger J, et al. Plasma transfusion
in liver transplantation: a randomized, double-blind, multi-
center clinical comparison of three virally secured plasmas.
Transfusion 2013;53:1335-45.
107. Bindi ML, Miccoli M, Marietta M, et al. Solvent detergent
vs. fresh frozen plasma in cirrhotic patients undergoing liver
transplant surgery: a prospective randomized control study.
Vox Sang 2013;105:137-43.
108. Stensballe J, Ulrich AG, Nilsson JC, et al. Resuscitation of end-
otheliopathy and bleeding in thoracic aortic dissections: the
VIPER-OCTA randomized clinical pilot trial. Anesth Analg
2018;127:920-7.
109. Tølløfsrud S, Noddeland H, Svennevig JL, et al. Universal
fresh frozen plasma (Uniplas): a safe product in open-heart
surgery. Intensive Care Med 2003;29:1736-43.
110. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized
trial of solvent/detergent-treated and standard fresh-frozen
plasma in the coagulopathy of liver disease and liver trans-
plantation. Transfusion 1999;39:1227-34.
111. Noddeland H, Tollofsrud S, Svennevig J, et al. Universal
solvent/detergent-treated fresh frozen plasma (Uniplas--
rationale and clinical properties). Thromb Res 2002;107(Suppl
1):S33-7.
112. Trueman P, Drummond M, Hutton J. Developing guidance
for budget impact analysis. Pharmacoeconomics 2001;19:
609-21.
113. Custer B, Hoch JS. Cost-effectiveness analysis: what it really
means for transfusion medicine decision making. Transfus
Med Rev 2009;23:1-12.
114. Custer B. Health economics and blood safety. In: Shan H
Dodd RY , editors. Blood Safety: A Guide to Monitoring and
Responding to Potential New Threats. New York: Springer
International Publishing; 2019. p. 53-81.
115. de Sousa G, Seghatchian J. Highlights of PBTI Coimbra Con-
ference on PRT of plasma & current opinions on pathogen
reduction treatment of blood components. Transfus Apher Sci
2015;52:228-32.
116. Seltsam A, Muller TH. Update on the use of pathogen-
reduced human plasma and platelet concentrates. Br J
Haematol 2013;162:442-54.
117. Prowse CV. Component pathogen inactivation: a critical
review. Vox Sang 2013;104:183-99.
118. Di Minno G, Navarro D, Perno CF, et al. Pathogen reduction/
inactivation of products for the treatment of bleeding disor-
ders: what are the processes and what should we say to
patients? Ann Hematol 2017;96:1253-70.
119. Yonemura S, Doane S, Keil S, et al. Improving the safety of
whole blood-derived transfusion products with a riboﬂavin-
based pathogen reduction technology. Blood Transfus 2017;
15:357-64.
120. Cancelas JA, Gottschall JL, Rugg N, et al. Red blood cell con-
centrates treated with the amustaline (S-303) pathogen reduc-
tion system and stored for 35 days retain post-transfusion
viability: results of a two-centre study. Vox Sang 2017;112:
210-8.
121. Drew VJ, Barro L, Seghatchian J, et al. Towards pathogen
inactivation of red blood cells and whole blood targeting viral
DNA/RNA: design, technologies, and future prospects for
developing countries. Blood Transfus 2017;15:512-21.
122. Wiltshire M, Meli A, Schott MA, et al. Quality of red cells after
combination of prion reduction and treatment with the inter-
cept system for pathogen inactivation. Transfus Med 2016;26:
208-14.
123. Allain JP, Owusu-Ofori AK, Assennato SM, et al. Effect of plas-
modium inactivation in whole blood on the incidence of
TRANSFUSION 21
PROCEEDINGS OF FDA WORKSHOP
blood transfusion-transmitted malaria in endemic regions: the
African Investigation of the Mirasol System (AIMS)
randomised controlled trial. Lancet 2016;387:1753-61.
124. Membe SK, Coyle D, Husereau D, et al. Octaplas Compared
with Fresh Frozen Plasma to Reduce the Risk of Transmitting
Lipid-Enveloped Viruses: An Economic Analysis and Budget
Impact Analysis. Ottawa ON: Canadian Agency for Drugs and
Technologies in Health (CADTH); 2011.
125. Cicchetti A, Coretti S, Sacco F, et al. Budget impact of
implementing platelet pathogen reduction into the
Italian blood transfusion system. Blood Transfus 2018;16:
483-9.
126. Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, et al.
Reducing the ﬁnancial impact of pathogen inactivation tech-
nology for platelet components: our experience. Transfusion
2014;54:158-68.
127. Walsh GM, Shih AW, Solh Z, et al. Blood-Borne Pathogens: A
Canadian Blood Services Centre for Innovation Symposium.
Transfus Med Rev 2016;30:53-68.
128. Jacquot C, Delaney M. Efforts toward elimination of infectious
agents in blood products. J Intensive Care Med 2018;33:
543-50.
129. Picker SM, Schneider V, Oustianskaia L, et al. Cell viability
during platelet storage in correlation to cellular metabolism
after different pathogen reduction technologies. Transfusion
2009;49:2311-8.
130. Schubert P, Johnson L, Marks DC, et al. Ultraviolet-based
pathogen inactivation systems: untangling the molecular
targets activated in platelets. Front Med (Lausanne) 2018;
5:129.
131. Rock G. A comparison of methods of pathogen inactivation of
FFP. Vox Sang 2011;100:169-78.
132. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced plate-
lets for the prevention of bleeding. Cochrane Database Syst
Rev 2013;3:CD009072.
133. Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced
platelets for the prevention of bleeding. Cochrane Database
Syst Rev 2017;7:CD009072.
134. Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a
novel riboﬂavin-based technology for pathogen reduction and
white blood cell inactivation. Transfus Med Rev 2008;22:
133-53.
135. Henschler R, Seifried E, Mufti N. Development of the S-303
pathogen inactivation technology for red blood cell concen-
trates. Transfus Med Hemother 2011;38:33-42.
136. Nkohkwo A, Agbor G, Asongalem E, et al. Whole blood patho-
gen reduction technology and blood safety in sub-Saharan
Africa: a systematic review with regional discussion. Afr J Lab
Med 2016;5:363.
137. Stramer SL. Current perspectives in transfusion-transmitted
infectious diseases: emerging and re-emerging infections.
ISBT Sci Ser 2014;9:30-6.
138. Bah A, Cardoso M, Seghatchian J, et al. Reﬂections on the
dynamics of bacterial and viral contamination of blood com-
ponents and the levels of efﬁcacy for pathogen inactivation
processes. Transfus Apher Sci 2018;57:683-8. https://doi.org/
10.1016/j.transci.2018.09.004.
139. McCullough J, Alter HJ, Ness PM. Interpretation of pathogen
load in relationship to infectivity and pathogen reduction efﬁ-
cacy. Transfusion 2018;59:1132-46. https://doi.org/10.1111/trf.
15103.
140. Hauser L1, Roque-Afonso AM, Beylouné A, et al. Hepatitis E
transmission by transfusion of intercept blood system-treated
plasma. Blood 2014;123:796-7.
141. Mirasol Evaluation of Reduction in Infections Trial
(MERIT). ClinicalTrials.gov. Mirasol Evaluation of Reduc-
tion in Infections Trial (MERIT) [Internet]. Identiﬁer
NCT03737669. Bethesda (MD): National Library of Medi-
cine; 2018. Available from: https://clinicaltrials.
gov/ct2/show/NCT03737669.
142. Lozano M, Cid J. Analysis of reasons for not implementing
pathogen inactivation for platelet concentrates. Transfus Clin
Biol 2013;20:158-64.
143. Goodrich RP, Segatchian J. Special considerations for
the use of pathogen reduced blood components in
pediatric patients: an overview. Transfus Apher Sci 2018;57:
374-7.
144. JICA Hands over Blood Safety Technology Project to
National Blood Service. National Blood Service Ghana. [cited
2018 Sep 17]. Available from: https://nbsghana.org/jica-
hands-over-blood-safety-technology-project-to-national-
blood-service/.
145. Winter KM, Johnson L, Kwok M, et al. Red blood cell in vitro
quality and function is maintained after S-303 pathogen inac-
tivation treatment. Transfusion 2014;54:1798-807.
146. North A, Ciaravino V, Mufti N, et al. Preclinical pharmacoki-
netic and toxicology assessment of red blood cells prepared
with S-303 pathogen inactivation treatment. Transfusion 2011;
51:2208-18.
147. Mufti NA, Erickson AC, North AK, et al. Treatment of whole
blood (WB) and red blood cells (RBC) with S-303 inactivates
pathogens and retains in vitro quality of stored RBC. Biologi-
cals 2010;38:14-9.
148. Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell
viability is maintained after treatment with a second-
generation S-303 pathogen inactivation process. Transfusion
2011;51:2367-76.
149. Brixner V, Kiessling AH, Madlener K, et al. Red blood cells
treated with the amustaline (S-303) pathogen reduction sys-
tem: a transfusion study in cardiac surgery. Transfusion 2018;
58:905-16.
150. JICA hands over blood safety technology project to MOH
[Internet]. Accra, Ghana: BusinessGhana; 2018 [cited 2018 Sep
14]. Available from: https://www.businessghana.com/site/
news/business/172359/JICA-hands-over-blood-safety-
technology-project-to-MOH.
151. “Efﬁcacy and Safety of RBCs Derived From Mirasol-treated
Whole Blood in Patients Requiring Chronic Transfusion
(PRAISE).” [cited 2019 Feb 5]. Available from: https://
clinicaltrials.gov/ct2/show/NCT03329404.
22 TRANSFUSION
ATREYA ET AL.
152. Trakhtman P, Kumukova I, Starostin N, et al. The pathogen-
reduced red blood cell suspension: single centre study of clini-
cal safety and efﬁcacy in children with oncological and
haematological diseases. Vox Sang 2019;114:223-31.
153. Kumar V, Lockerbie O, Keil SD, et al. Riboﬂavin and UV-light
based pathogen reduction: extent and consequence of DNA
damage at the molecular level. Photochem Photobiol 2004;80:
15-21.
154. Marschner S, Goodrich R. Pathogen reduction technology
treatment of platelets, plasma and whole blood using riboﬂa-
vin and UV light. Transfus Med Hemother 2011;38:8-18.
155. Cancelas JA, Rugg N, Pratt PG, et al. Red cells from riboﬂavin
plus UV-light treated whole blood can be effectively radio-
labeled with 51-Cr for viabiliity studies. Transfusion 2009;49
(S3):108A (S44).
156. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of
stored red blood cells derived from riboﬂavin plus ultraviolet
light-treated whole blood. Transfusion 2011;51:1460-8.
157. Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen
reduction of Trypanosoma cruzi with riboﬂavin and ultravio-
let light for whole blood. Transfusion 2012;52:409-16.
158. El Chaar M, Atwal S, Freimanis GL, et al. Inactivation of Plas-
modium falciparum in whole blood by riboﬂavin plus irradia-
tion. Transfusion 2013;53:3174-83.
159. Fast LD, Nevola M, Tavares J, et al. Treatment of whole blood
with riboﬂavin plus ultraviolet light, an alternative to gamma
irradiation in the prevention of transfusion-associated graft-
versus-host disease? Transfusion 2013;53:373-81.
160. Reddy HL, Doane SK, Keil SD, et al. Development of a riboﬂa-
vin and ultraviolet light-based device to treat whole blood.
Transfusion 2013;53(Suppl 1):131S-6S.
161. Tonnetti L, Thorp AM, Reddy HL, et al. Riboﬂavin and ultravi-
olet light reduce the infectivity of Babesia microti in whole
blood. Transfusion 2013;53:860-7.
162. Okoye OT, Reddy H, Wong MD, et al. Large animal evaluation
of riboﬂavin and ultraviolet light-treated whole blood transfu-
sion in a diffuse, nonsurgical bleeding porcine model. Trans-
fusion 2015;55:532-43.
163. Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al. Treatment of
whole blood with riboﬂavin and UV light: impact on
malaria parasite viability and whole blood storage. Shock
2015;44(Suppl 1):33-8.
164. Tonnetti L, Thorp AM, Reddy HL, et al. Reduction of Leish-
mania donovani infectivity in whole blood using riboﬂavin
and ultraviolet light. Transfusion 2015;55:326-9.
165. Cancelas JA, Slichter SJ, Rugg N, et al. Red blood cells derived
from whole blood treated with riboﬂavin and ultraviolet light
maintain adequate survival in vivo after 21 days of storage.
Transfusion 2017;57:1218-25.
166. Corash L. Inactivation of infectious pathogens in labile blood
components: meeting the challenge. Transfus Clin Biol 2001;
8:138-45.
167. Dupuis K, Bernard K, Jones S, et al. Helinx technology inacti-
vates pathogens of emerging importance in red blood cell
concentrates. Blood 2003;102(Suppl. 1):816a.
168. Hanson D, Propst M, Dupuis K. High titer leukocyte inactiva-
tion in INTERCEPT red blood cells (RBC). Vox Sang 2001;
101a:81.
169. Mikovits JA, Hagen K, Liu W, et al. Inactivation of XMRV
in platelet and RBC components prepared with the
INTERCEPT blood system. Rev Antivir Ther Infect Dis
2010;8:36.
170. Specht KG, Kittler L, Midden WR. A new biological target of
fucomarians: photochemical formation of covalent adducts
with unsaturated fatty acids. Photochem Photobiol 1988;47:
537-41.
171. Skripchenko A, Wagner SJ, Thompson-Montgomery D, et al.
Thiazole orange, a DNA binding photochemical with ﬂexible
structure, can inactivate pathogens in red cell suspensions
while maintaining red cell storage properties. Transfusion
2006;46:213-9.
172. Wagner SJ, Skripchenko A, Salata J, et al. Inactivation of
Leishmania donavani infantum and Trypanosoma cruzi in red
cell suspensions by thiazole orange. Transfusion 2008;48:
1363-7.
173. Dai T, Gupta A, Huang YY, et al. Blue light rescues mice from
potentially fatal Pseudomonas aeruginosa burn infection: efﬁ-
cacy, safety, and mechanism of action. Antimicrob Agents
Chemother 2013;57:1238-45.
174. Maclean M, McKenzie K, Anderson JG, et al. 405 nm light
technology for the inactivation of pathogens and its potential
role for environmental disinfection and infection control.
J Hosp Infect 2014;88:1-11.
175. Maclean M, White T, Anderson JG, et al. A new proof-of-
concept in bacterial reduction: antimicrobial action of violet-
blue light (405 nm) in ex vivo stored plasma. J Blood Transfus
2016;2016:2920514.
176. Maclean M, MacGregor SJ, Anderson JG, et al.
Inactivation of bacterial pathogens following exposure to
light from a 405-nm LED array. Appl Environ Microbiol
2009;75:1932-7.
177. Tomb RM, Maclean M, JE Coia E, et al. Investigating the inﬂu-
ence of biologically-relevant suspending media on 405 nm
light inactivation of feline calicivirus: a surrogate of norovirus.
Food Environ Virol 2017;9:159-67.
178. Gonzales R, Taylor AL, Atkinson AJ, et al. US Army blood
program: 2025 and beyond. Transfusion 2016;56(Suppl 1):
S85-93.
179. Reddoch-Cardenas KM, Bynum JA, Meledeo MA, et al.
Cold-stored platelets: A product with function optimized
for hemorrhage control. Transfus Apher Sci 2019;58:
16-22.
180. Hoffmeister KM, Felbinger TW, Falet H, et al. The
clearance mechanism of chilled blood platelets. Cell 2003;
112:87-97.
181. Apelseth TO, Kristoffersen EK, Kvalheim VL, et al. Transfusion
with cold stored platelets in patients undergoing complex car-
diothoracic surgery with cardiopulmonary bypass circulation:
effect on bleeding and thromboembolic risk. Transfusion
2017;57:3A-4A.
TRANSFUSION 23
PROCEEDINGS OF FDA WORKSHOP
182. Johnson L, Cameron M, Waters L, et al. The impact of refrig-
erated storage of UVC pathogen inactivated platelet concen-
trates on in vitro platelet quality parameters. Vox Sang 2019;
114:47-56.
183. Waters L, Cameron M, Padula MP, et al. Refrigeration,
cryopreservation and pathogen inactivation: an updated
perspective on platelet storage conditions. Vox Sang 2018;
113:317-28.
184. Pidcoke HF, McFaul SJ, Ramasubramanian AK, et al.
Primary hemostatic capacity of whole blood: a
comprehensive analysis of pathogen reduction and
refrigeration effects over time. Transfusion 2013;53(Suppl
1):137S-49S.
185. Meledeo MA, Peltier GC, McIntosh CS, et al. Hemostatic func-
tional preservation of refrigerated whole blood over 35 days.
Transfusion 2018;58:62A.
186. Cap AP, Perkins JG. Lyophilized platelets: challenges and
opportunities. J Trauma 2011;70(5 Suppl):S59-60.
187. Cap AP, Pidcoke HF, Keil SD, et al. Treatment of blood with a
pathogen reduction technology using ultraviolet light and
riboﬂavin inactivates Ebola virus in vitro. Transfusion 2016;56
(Suppl 1):S6-15.
24 TRANSFUSION
ATREYA ET AL.
